Microbial Dysbiosis Tunes the Immune Response Towards Allergic Disease Outcomes

Tracy Augustine1 · Manoj Kumar2 · Souhaila Al Khodor2 · Nicholas van Panhuys1

Accepted: 7 April 2022 / Published online: 1 June 2022
© The Author(s) 2022

Abstract
The hygiene hypothesis has been popularized as an explanation for the rapid increase in allergic disease observed over the past 50 years. Subsequent epidemiological studies have described the protective effects that in utero and early life exposures to an environment high in microbial diversity have in conferring protective benefits against the development of allergic diseases. The rapid advancement in next generation sequencing technology has allowed for analysis of the diverse nature of microbial communities present in the barrier organs and a determination of their role in the induction of allergic disease. Here, we discuss the recent literature describing how colonization of barrier organs during early life by the microbiota influences the development of the adaptive immune system. In parallel, mechanistic studies have delivered insight into the pathogenesis of disease, by demonstrating the comparative effects of protective T regulatory (Treg) cells, with inflammatory T helper 2 (Th2) cells in the development of immune tolerance or induction of an allergic response. More recently, a significant advancement in our understanding into how interactions between the adaptive immune system and microbially derived factors play a central role in the development of allergic disease has emerged. Providing a deeper understanding of the symbiotic relationship between our microbiome and immune system, which explains key observations made by the hygiene hypothesis. By studying how perturbations that drive dysbiosis of the microbiome can cause allergic disease, we stand to benefit by delineating the protective versus pathogenic aspects of human interactions with our microbial companions, allowing us to better harness the use of microbial agents in the design of novel prophylactic and therapeutic strategies.

Keywords Adaptive immunity · Microbiome · CD4+ · Hygiene · Allergy · Atopy

Introduction
Atopic diseases such as asthma, hay fever, atopic dermatitis, and food allergies represent the most common forms of allergy and are typically defined by the presence of specific immunoglobulin E (sIgE) in serum or a positive skin prick test for common environmental allergens. Constituting the most prevalent chronic condition of childhood, significant proportions of children develop atopic symptoms in their first year of life. One recent multinational study indicated that 14–28% of infants suffer from atopic dermatitis [1] and rates of recurrent, severe wheezing often used as an early diagnostic marker of heightened risk for the development of asthma have been reported at 16% [2], with some western countries reporting rates of food allergy in excess of 10% at 12 months of age [3]. Increases in the prevalence of these conditions have largely been observed in industrialized countries and have been linked to the modern western diet and lifestyle. Although, there is now also growing evidence of increasing rates of disease in rapidly developing countries, showing a correlation with rising economic growth and changes in diet and lifestyle [4]. Numerous studies indicate that these types of allergic responses often occur in a progressive manner termed the “atopic march,” initially presenting early in infants as a skin allergy or eczema that is linked to an underlying food allergy [5]. Subsequently, many children go on to become sensitized to indoor allergens, such as dust or pet dander and to develop allergic rhinitis and then asthma later in childhood or in their early teenage years [5]. Sensitization to outdoor aeroallergens such as grass and tree pollens typically occurs during the later phases of the atopic march, at a time where sensitization to
food allergens may be seen to decrease [6]. The presence of atopy early in life has been shown to significantly increase the risk for development of additional sensitizations, resulting in a progressive form of atopic disease that advances in an additive fashion [7]. Children initially presenting with atopic dermatitis, the most commonly diagnosed form of atopy within the first 6 months following birth show increased risk for the development of asthma and allergic rhinitis, with the incidence of subsequent disease being associated to the severity of the initially diagnosed atopic dermatitis [5]. These findings imply that certain individuals are predisposed to the development of atopic disease, and early age of onset may be indicative of a susceptible phenotype predictive of increased risk for multiple sensitizations [7]. Many risk factors are associated with the onset of atopic disease, including parental history of atopy [8], breast milk vs. formula feeding [9–12], diet [13], air pollution [14], use of antibiotics [15–17], and mode of delivery [18–20], having been well characterized through epidemiological studies. Whereas data describing the mechanisms linking these environmental factors with the aberrant activation of the adaptive immune system that is responsible for the onset of disease have lagged behind.

The adaptive immune system plays a pivotal role in the development of defense against potential infectious pathogens [21] and as the primary function of the adaptive immune system is to protect against invading pathogens, immune responses generally have an inflammatory effect with potential immunopathological consequences that need to be tightly controlled. To identify potential pathogens, the adaptive immune system requires the ability to distinguish between self and non-self-antigens, whilst simultaneously discerning harmless environmental antigens which can be safely ignored [22]. Occasionally, a failure in the system of checks and balances that is required to maintain immune tolerance occurs, resulting in either autoimmune disease elicited against self-antigens or development of allergic disease against otherwise harmless environmental antigens [23], with studies demonstrating the influence of genetic, developmental, and environmental factors, all contributing to the breakdown of immune tolerance that causes disease [24–27]. Although, significant variations occur, the majority of allergic responses are manifested in early childhood when the immune system is still developing [28–30]. Here, the role of T cells in the initiation of an allergic response has been widely studied, with helper T cells, particularly cells of the Th2 lineage being characterized as the major mediator involved in eliciting allergic responses. Subsequently, it has been determined that a balance between inflammatory Th2 and suppressive Treg cells exists that controls the threshold for allergen sensitization [31] (Fig. 1).

**Fig. 1** Influences of environmental and microbial interactions on adaptive immune responses and allergic disease. A wide array of factors including, genetic, environmental, and dietary inputs can all potentially modulate the gut immune-microbiome axis and influence the occurrence of allergy. The microbiome in turn modulates the cohort of regulatory cells induced during development and allows for the establishment of a tolerogenic environment, which mediates the suppression of T cells that arise from inflammatory lineages. However, a dysbiosis of the microbiome leads to impairment of this tolerogenic environment leading to development of allergic diseases along with greater expansion in cells of the Th2 inflammatory lineage.
The recent development of “omic” sequencing techniques allowing for the rapid and affordable sequencing of the microbiota has led to studies that have revealed the relevance of the microbiome as a key environmental factor [32, 33]. Allowing us to begin to elucidate how exposure to the natural microbial environment influences the development of the immune system, especially at sites integral for barrier immunity, with new data indicating that host-microbiome interactions during early development play a significant determining role in shaping the immune responses of the host [34, 35].

**Microbial Exposures and the Development of Allergic Disease**

**Atopic Dermatitis**

Atopic dermatitis, otherwise known as atopic eczema, is an inflammatory skin disorder which mostly develops in childhood and is characterized by itchy eczematous lesions [36]. Atopic dermatitis affects nearly 15–20% of children and 1–3% of adults worldwide [37, 38]. Multiple risk factors contribute to the development of atopic dermatitis, which has a close association with food allergy, particularly in early childhood. The earlier the onset of atopic dermatitis, the higher the risk of food allergy, particularly in relation to peanut, cow’s milk, and hen’s egg allergens [36]. Patients with atopic dermatitis exhibit an increase in the skin pH and lipid deficiency during disease flares, along with the degradation of the skin barrier function [39].

Recently, the skin microbiome has been identified as a critical factor in the development of atopic dermatitis (Table 1) [40–43]. Microbial diversity has been described to have an inverse correlation with atopic dermatitis score (SCORAD), with decreased microbial diversity at sites of disease progression [44]. Specifically, an increase in the relative abundance, particularly of *Firmicutes* (Gemella spp., *Staphylococcus aureus* [44] and *Staphylococcus epidermidis* and a decrease in the abundance of the phylum *Actinobacteria* (*Dermacoccus* spp.) [45] and Proteobacteria [34] and the genera *Streptococcus, Corynebacterium,* and *Cutibacterium* has been associated with atopic dermatitis [34]. Byrd et al. showed that a greater predominance of *Staphylococcus aureus* occur in patients with more severe disease and *Staphylococcus epidermidis* is predominant in patients with less severe disease [46]. *Staphylococcus aureus* strains isolated from patients with atopic dermatitis were enriched with the CC1 strains, whereas the healthy control population was enriched with the CC30 strains [47]. Additionally, topical colonization of mice using strains isolated from patients with atopic dermatitis or controls showed that *Staphylococcus aureus* isolates from patients with more severe disease flares are capable of inducing epidermal thickening and expansion of cutaneous Th2 and Th17 cells, indicating that functional differences in these distinct staphylococcal strains can contribute to the complexity of atopic dermatitis [46].

In addition to the role of the skin microbiome, the composition of the gut microbiome was similarly found to be altered in patients with atopic dermatitis who exhibited a low gut microbial diversity which was also associated with disease [48–54]. The composition of the gut microbiome in 1-month-old infants from the KOALA birth cohort study showed that colonization with *Clostridium difficile* led to an increased risk of development of atopic dermatitis and other allergic diseases [33]. Furthermore, atopic dermatitis has been associated with an increased abundance of *Firmicutes*, specifically the *Clostridium difficile, Coprobacillus* spp., *Enterococcus* spp., and *Peptoniphilus* spp. and a decreased abundance of Proteobacteria and Bacteroidetes in the intestine [54, 55], potentially due to a lack of exposure to the LPS contained in the cell walls of Proteobacteria, which exerts a protective action through boosting IL-12 production by monocytes and dendritic cells to induce responses [56], which may otherwise be impaired in pediatric atopic dermatitis patients [55]. Bacterial metabolites synthesized by the gut microbiome also play a pivotal role in providing protection against the development of atopic dermatitis [57]. As the intestinal barrier function can be impaired in those patients [58], with impairment often being associated with an enrichment of *Fecalibacterium*, in particular, *Fecalibacterium prausnitzii*, a non-short chain fatty acid (SFCA)-producing bacteria which is especially common in pediatric atopic dermatitis [59] and can lead to an increased inflammation of the gut epithelium in these patients [60]. Alternately, SFCA-producing bacteria can upregulate the expression of tight junction to improve the intestinal barrier function [55]. Moreover, SCFAs like butyrate can regulate the activation and proliferation of colonic Treg cells, which has been shown to be protective in mouse models of disease [57, 61].

**Atopic Food Allergies**

Food allergy is a condition that has shown a significant increase in prevalence over the last 20 years [62], now affecting nearly 8% of children and 5% of adults worldwide [63]. The eight most common food allergens in young children are cow’s milk (2.5%), egg (1.3%), peanut (0.8%), wheat and soy (nearly 0.4% each), tree nuts (0.2%), and fish and shellfish (0.1% each) [64]. Food allergies can be broadly classified as resulting from immune pathways that activate effector cells through food-allergen specific IgE or non-IgE-mediated mechanisms, [64, 65]. Oral tolerance is induced under homeostatic conditions and leads to the suppression of immune
Table 1  Microbial colonization and associations with allergic disease

| Allergy type       | Location | Phylum       | Family/species/genera                        | Relative abundance | Influence on immune functions |
|--------------------|----------|--------------|---------------------------------------------|--------------------|------------------------------|
| Atopic dermatitis  | Skin     | Firmicutes   | Gemella spp, Staphylococcus aureus [40, 44, 45] | Increase in abundance | - S. aureus produces toxins that accentuate allergic disease through induction of toxin-specific IgE, in addition to activation of various cell types including Th-2 cells, eosinophils, and keratinocytes [44]  
- Superantigens from S. aureus can cause an upregulation of cutaneous lymphocyte antigen expression by T cells by stimulating production of IL-12, thereby promoting homing to the skin [44]  
- S. aureus can induce a Th2 response through proinflammatory lipoproteins which induce thymic stromal lymphopoietin expression in primary human keratinocytes in a TLR2/TLR6-dependent manner [40]  
- Bacterial challenge assays in keratinocytes and monocyte-derived dendritic cells showed distinct IL-1-mediated innate and Th1-mediated adaptive immune responses with S. aureus and S. epidermidis [45]  
- Induction of a Th1 polarizing cytokine signature (IL12p70 and IL12p40) shown in response to S. epidermidis in vitro conditions [45]  
- Neonates exposed to S. epidermidis can lead to production of antigen-specific CD4+ T cells, which are mostly Treg cells. The delay in the exposure to S. epidermidis until adulthood causes inflammatory cytokine-producing effector CD4+ T cells to predominate [34]  
- S. epidermidis colonization induces IL17A+CD8+ T cells that can home to the epidermis leading to the enhancement of innate barrier immunity and thereby limits invasion by pathogens [41] |
|                    |          | Actinobacteria | Dermacoccus spp. [45]                        | Decrease in abundance | Mycolic acid present in the cell envelope of several members of Corynebacterium genus can specifically induce IL-17A+ dermal γδ T cells [42] |
|                    |          | Deinococota   | Deinococcus [45]                            | Decrease in abundance |                               |
|                    |          | Proteobacteria | Methylobacterium Haemophilus [45]            | Decrease in abundance |                               |
|                    |          | Genera Streptococcus, Corynebacterium, Cutibacterium [34, 43, 42] |                        | Decrease in abundance |                               |
| Allergy type | Location | Phylum     | Family/species/ genera                                                                 | Relative abundance | Influence on immune functions                                                                                                                                 |
|--------------|----------|------------|----------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gut          |          | Firmicutes | *Clostridium difficile* [33, 49],  
*Coprobacillus* spp.,  
*Peptoniphilus* spp. [54],  
*Enterococcus* spp. [54, 55]  
*Fecalibacterium praunitzii* [59] | Increase in abundance | Increase in abundance  
Chronic progression of atopic dermatitis is associated with dysbiosis of *Fecalibacterium praunitzii* which causes an impairment of gut epithelial barrier leading to aberrant Th2 type immune responses against allergens in the skin [59] |
| Actinobacteria |          |            | *Eggerthella* spp. [54]  
*Bifidobacterium* [48–50] | Increase in abundance | Increase in abundance  
*Bifidobacterium longum AH1206 can induce Treg cells and has been shown to be protective against respiratory allergic inflammation [50] |
| Proteobacteria |          |            | *Escherichia coli* [33]  
*Sutterella* spp. [51, 54, 56] | Increase in abundance | Decrease in abundance  
Endotoxin from Proteobacteria enhances IL-12 production from monocytes and dendritic cells and thereby elicits a Th1 response [56]. Increased risk of atopic eczema is associated with low exposure to the endotoxin [51] |
| Fusobacteria |          |            | *Fusobacterium* spp. [54] | Decrease in abundance |  
- *Bacteroides fragilis* suppresses production of inflammatory cytokines TNF-α and IL-23, thereby preventing induction of colitis, in an experimental colitis model [52]  
- *Bacteroides fragilis* elicits mucosal tolerance by mediating conversion of CD4+ T cells into IL-10 producing FOXP3+ Tregs as shown in a murine model [53] |
| Bacteroidetes |          |            | *Bacteroides* [52–55] | Decrease in abundance |  
Bacteroidetes |          |            | *Enterobacteriaceae* [77] | Increase in abundance | Increase in abundance |
| Food allergy | Gut      |            | *Citrobacter* [78] | Decrease in abundance (Food allergy) |  
*Haemophilus* [78] | Decrease in abundance (Food sensitization) |
|              | Proteobacteria |            | *Bacteroidaceae* [77] | Decrease in abundance |  
Firmicutes |          |            | *Ruminococcaceae* [77] | Decrease in abundance |
| Allergy type | Location | Phylum | Family/species/ genera | Relative abundance | Influence on immune functions |
|--------------|----------|--------|-------------------------|-------------------|--------------------------------|
| Dailister, Dorea and Clostridium [73–75, 78] | Decrease in abundance (Food sensitization) |
| Oscillospora, Lactococcus and Dorea [76, 78] | Decrease in abundance (Food allergy) |
| Allergic Rhinitis | Proteobacteria | Prevotella, Neisseria and Moraxella species [97] | Increase in abundance |
| Asthma | Lung | Firmicutes | Selenomonas species and Butyribrio species [97] | Increase in abundance |
| | | Blautia and Lachnospiraceae inserta sedis [101] | Increase in abundance in eosinophil-low asthma patients |
| | | Aeribacillus, Virgibacillus and Caldalkalibacillus [101] | Increase in abundance in eosinophil-high asthma patients |
| | Proteobacteria | Neisseria [88, 101], | Increase in abundance in eosinophil-low asthma patients |
| | | Haemophilus parainfluenzae [104] | Increase in abundance in corticosteroid-resistant asthma |
| | | Haemophilus and Moraxella species [90, 102, 103] | Decrease in abundance Neutrophilic asthma |
| | Bacteroidetes | Prevotella species [97] | Increase in abundance |
| | | Bacteroides [101] | Increase in abundance in eosinophil-low asthma patients |
| | | Actinobacteria | Actinomyces and Rothia [101] | Increase in abundance in eosinophil-low asthma patients |
responses to food-derived foreign antigens encountered in the gastrointestinal tract [66]. The loss of oral tolerance initiates a cascade of immune responses against otherwise innocuous food antigens resulting in food allergy [67]. As at other sites of barrier immunity, Treg cells play a key role in maintenance of tolerance by regulating immune responses to allergens through several mechanisms, including the production of the inhibitory cytokines IL-10 and TGF-β [68], by inhibiting the proliferation of effector T cells, depriving the cells of IL-2 [69] and through the production of granzymes A and B that can cause cytolysis of effector T cells [68]. Several recent findings suggest that the SCFA, butyrate, contributes to the development of oral immune tolerance due to its strong anti-inflammatory effects [70, 71]. Emerging 16S rRNA sequencing–based studies on food allergy and sensitization indicate that gut dysbiosis may precede the development of food allergy (Table 1) [72–76]. The Canadian Healthy Infant Longitudinal Development (CHILD) study indicated that a reduced gut microbial diversity at 3–6 months was associated with an increased tendency for food sensitization at 12 months and showed an increased abundance of Enterobacteriaceae and a decreased abundance of Bacteroidaceae and Ruminococcaceae [77]. A US pediatric cohort study determined that a lower abundance of Citrobacter, Oscillospora, Lactococcus, and Dorea in stool samples collected at 3–6 months of age was associated with food allergy by age three and a relatively lower abundance of Haemophilus, Dailister, Dorea, and Clostridium in stool samples of the same age group exhibited food sensitization by age 3 to at least one of the eight major food allergens [78]. Whereas clostridia exhibits a protective effect against sensitization to food allergens through regulation of the innate lymphoid cell function and intestinal cell permeability [55]. Although the gut microbiome changes with time, the most rapid changes occur early in life and are mainly influenced by whether the infants are vaginally delivered or via Cesar-ean section (C-section) and breast- or formula-fed [79]. In addition, antibodies, such as IgA at the mucosal surface of the intestine, can diffuse across the gut epithelium into the lumen to bind and prevent an inappropriate crossing of intestinal microbiota into the bloodstream [80]. With IgA levels being essential for the maintenance of intestinal homeostasis and the regulation of gut microbiota composition [81], especially during the post-natal period where IgA is transferred to infants through maternal breast milk and plays a vital role in immune and microbial homeostasis. Intriguingly, a recent study by Abdel-Gadir et al. [82] reported a decrease in binding of fecal bacteria to IgA and an increased binding to IgE in infants with food allergy revealing a previously undescribed allergic response to commensals in the intestine of food allergic patients.

Table 1 (continued)

| Allergy type Location Phylum Family/species/ genera | Relative abundance | Influence on immune functions |
|---------------------------------------------------|-------------------|-------------------------------|
| Nesterenkoni [101] Increase in abundance in eosinophil-high asthma patients Proteobacteria Clostridium neocatallae [106] Increase in abundance Firmicutes Blautia and Ruminococcus [107] Increase in abundance for asthma Faecalibacterium [85, 107] and Roseburia | Increase in abundance | Increase in abundance in infants at high-risk |
| Clostridium [107] and Blautia [107] | Increase in abundance | Increase in abundance |
| Lachnospira [85] and Veillonella | Decrease in abundance | Decrease in abundance |
| Actinobacteria Rothia [85] | Decrease in abundance | Decrease in abundance |
Asthma and Allergic Rhinitis

Asthma is a common allergic inflammatory disease affecting more than 300 million people worldwide [83]. Broadly, asthma can be defined to be of either an atopic or non-atopic phenotype. In atopic asthma, the incidence of asthma symptoms occurs later in childhood or in early teenage years and may be resultant of an underlying genetic predisposition to allergen-sensitivity leading to development of hyper-responsiveness with symptoms mostly persisting into adulthood [84]. Whereas, non-atopic asthma largely develops within the first 2 to 3 years of age and develops as a neutrophil associated, recurring obstruction of the airways that typically resolves by around 13 years of age [84]. Several studies have reported the positive influence of microbial exposure on protection from the development of asthma, with children who are exposed to a highly diverse microbial environment often exhibiting lower rates of asthma and allergic rhinitis (Table 1) [24, 85–90]. For instance, in rural areas, children raised on farms are more likely to be exposed to livestock, as well as an increased likelihood of having consumed unpasteurized milk from farm animals during their early childhood [25, 91]. Such exposures to a microbial environment at a very young age are associated with a relatively lower risk of developing allergic diseases [92]. This is typically referred to as the “farm-effect” on allergic diseases and has been associated with both atopic and non-atopic phenotypes of asthma [92, 93]. Schuijs et al. reported that the ubiquitin-modifying enzyme A20 in the lung epithelium renders the protective effect in children living in farm environment, showing that the loss of A20 enzyme eliminated the protective effect; in addition, a single nucleotide polymorphism in the gene encoding for A20 enzyme was associated with allergy and asthma risk in children raised in a farm environment [94]. It was further shown that farm dust and bacterial LPS modify the communication between epithelial cells and dendritic cells, achieved through the induction of A20 expression [94], providing a possible explanation for the incidence of higher rates of asthma in children from urban areas, as compared to those from rural areas. Allergic rhinitis, also known as hay fever, is an atopic disease characterized by nasal congestion, sneezing, and rhinorrhea [95] and is predominantly caused by allergens such as pollen, dust mites, and animal dander; based on the causative allergen, allergic rhinitis can present as either seasonal or perennial in nature [96]. A recent analysis of the microbial composition in the mucosal airways of children with asthma or allergic rhinitis identified a decrease in certain groups of microbes and linked this microbial dysbiosis with the increased sensitization to allergic disease [97, 98]. Among those microbes found to constitute a healthy lung microbial composition were Bacteroidetes, Actinobacteria, and Firmicutes [83], whereas the phylum Proteobacteria was found to be abundant in asthmatics and was associated with lower levels of asthma control and increased numbers of asthma exacerbations [99, 100]. Other common microbial populations found in the mucosal airways of asthmatic patients include Prevotella, Selenomonas, Butyribrio, [97], and Neisseria [97, 101]. Some of these species, which includes Prevotella and Neisseria species, are also found associated with patients with allergic rhinitis [97]. Interestingly, the airway microbiome composition in patients with eosinophilic and neutrophilic asthma was found to be distinct, with the neutrophilic patients exhibiting a reduced diversity and richness in Proteobacteria and in particular, Haemophilus and Moraxella species [102, 103]. Haemophilus parainfluenzae is capable of activating the toll-like receptor (TLR) 4, which in turn leads to the transcription of pro-inflammatory cytokine IL-8 and inhibition of corticosteroid responses [104]. Apart from the airway microbiome, dysbiosis of the gut microbiome and lower gut microbial diversity early in life are also associated with a subsequent increased risk of developing asthma [105]. Data from the CHILD cohort study which examined children who were asthmatic at 4 years of age showed that the gut microbial composition of these children at 3 months of age exhibited a significant decrease in the abundance of the genus Lachnospira and an increased abundance of the species Clostridium neonatalae [106]. A further study which analyzed the gut microbial composition of infants at risk for asthma, during the first 100 days of their life, showed a decreased abundance of Lachnospira, Veillonella, and Faecalibacterium from the phylum Firmicutes and Rothia from the phylum Actinobacteria [85]. Yet another study showed that children with asthma had a significantly lower abundance of Faecalibacterium and Roseburia, belonging to the phylum Firmicutes, whereas Enterococcus and Clostridium from the same phylum were enhanced in these children as compared to healthy controls [107].

Early Life Exposures to Microbes and Immune System Development

Pre- and Post-Natal Colonization of Barrier Organs by the Microbiota

Until recently, it had been assumed that the prenatal environment was a sterile location, free from microbes. However, several studies published over the last decade have begun to question the “sterile womb” theory and whether prenatal colonization of the developing fetus does in fact occur [108–112]. The concept of a prenatal microbiome remains highly controversial and has been extensively reviewed [113, 114] and debated previously [115, 116]. New findings published in Mishra et al. [117] may present the best evidence for microbial exposure and colonization of fetal
organs by the microbiome. The authors showed that fetal organs contained a diverse array of bacterial species and that bacteria isolated from these organs can be grown under in vitro culture conditions. Bacterial structures were additionally visualized by electron microscopy in the 14-week-old fetal gut, with coincident staining for the presence of 16S rRNA by RNA in situ hybridization. Analysis of the T cell compartment revealed the presence of fetal memory T cells that were able to be expanded in the presence of the fetal-isolated bacterial strains. Whether these findings represent the identification of a definitive fetal microbial niche, indicative of a true host-microbe relationship or are merely evidence of persistent or transient colonization, still remains to be determined. However, evidence for the microbial priming of an adaptive immune response during the period of fetal growth has significant implications for the development of the immune system and may play a considerable role in the development of atopic disease susceptibility that has yet to be determined.

The exposure to the microbial environment early in postnatal life plays a significant role in the development of the immune system (see Table 2) [24]. The first few days after birth when neonates get their first major microbial inoculation represents a critical window in their immune system development [9, 118]. During this window, several factors can alter or influence the initial microbial colonization [24]. Among the potential factors, mode of delivery provides an initial strong primary determinant for post-natal colonization of microbial communities and associated barrier functions, playing a major role in the development of the subsequently established microbiome. During vaginal delivery, neonates acquire the major microbial communities from the mother, mainly characterized by an increased abundance of Bacteroides and Parabacteroides [119]. In contrast, babies born via C-section receive their first microbial inoculum from other sources, such as skin, saliva, or breast milk [119]. Interestingly, emerging evidence indicates that microbial communities acquired via vertical transmission are capable of adapting quickly to the new environment, and priming the associated immune functions, particularly LPS biosynthesis pathways and two-component systems pathways that are significantly under-presented in neonates born via C-section [120]. LPS, is a membrane component of Gram-negative bacteria and is capable of priming the neonatal immune system by stimulating secretion of pro-inflammatory cytokines at the interface of the earliest gut microbiome, which may result in persistent effects on neonatal physiology, including protective effects towards developing allergies later in life [86, 121]. On the other hand, an early perturbation of the host-commensal priming in neonates born via C-section can lead to defects in the proper education of the immune system [122] and higher propensities to develop chronic diseases later in life [123], with significant increases in the incidence of antibiotic resistant, hospital associated microbes being detected in several studies [124–126].

Apart from the mode of delivery, other environmental factors such as feeding with breast milk, staying in a joint family, or farm environment in the first few years of life can increase exposure to vast microbial diversity (Fig. 1), which may result in adequate immune responses against diverse microbial antigens; however, elimination of such microbial exposures either by feeding with formula milk, staying in a nuclear family, or exposures to antibiotics at a young age can promote inflammatory immune responses including those associated with asthma and other allergic diseases [24].

### Pre- and Post-Natal Development of the Adaptive Immune System

During pregnancy, the maternal immune system adopts a complex immunologic mechanism to enable the co-existence and maintenance of an equilibrium between both the maternal and developing fetal immune systems [13, 127]. In order to prevent fetal and placental immune rejection, whilst allowing for the unmatched tissue growth of the fetus as it prepares for adaptation to the external environment and the ensuing microbial colonization that occurs at birth [128]. The thymus becomes a functional organ of T cell development between the 7th and 16th week of gestation [129]. During the 8th week of gestation, early lymphoid progenitors originate from the liver and subsequently migrate into the thymus where they develop into naïve T cells [130]. Circulating T cells are observed around the 10th to 11th week of gestation following the development of a functional thymus [131]. Impaired growth of the fetal thymus has been shown to be related to several complications associated with pregnancy including preeclampsia, a condition which presents with reduced peripheral Treg cells in both the mother and newborn [132] and which in turn is associated with increased risk of allergic diseases development during childhood [133]. The fetal immune system is generally characterized as tolerogenic [134, 135], a feature essential for fetal survival [136]. During the gestational period, a substantial number of maternal cells cross the placenta to reside in the fetal lymph node which provokes the development of CD4+CD25hiFOXP3+ Treg cells. Various cytokines, hormones, and bacterial products including SCFAs and lipopolysaccharides are also involved in transplacental immune regulation [132, 137]. Fetal Treg cells suppress the proliferation and cytokine secretion of other potentially self-reactive T cells [134]. Human cord blood and infant blood are both characterized by a predominance of Th2 and Treg cells, as compared to Th1 or Th17 cells, which are more restricted in early life [134]. In fact, the Th2 and Treg phenotype bias in fetal tissues develops as early as the second trimester of pregnancy as identified from fetal spleen and lymph nodes.
Table 2  Pre- and post-natal microbial colonization of neonatal organs and associated immune functions

| Microbial colonization | Type of microbiome | Phylum | Family/species |
|------------------------|--------------------|--------|---------------|
| Pre-natal              | Skin and gut microbe | Firmicutes | Staphylococcus spp., and Lactobacillus spp. |
| Pre-natal              | Gut and skin microbe | Firmicutes, and Actinobacteria | Enterococcus faecium, Staphylococcus epidermidis, Streptococcus sanguinis, and Propionibacterium acnes |
| Pre-natal              | Oral, gut, skin and vaginal microbe | Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes, and Fusobacteria | Prevotella tannerae, Neisseria, Ureaplasma, Mycoplasma, and Escherichia coli |
| Pre-natal              | Gut and vaginal microbe | Firmicutes, Actinobacteria, Proteobacteria, and Fusobacteria | Lactobacillus, Gardnerella, Haemophilus, and Sneathia |
| Pre-natal              | Vaginal microbe | Firmicutes, and Actinobacteria | Lactobacillus and Micrococcus luteus |
| Post-natal             | Gut microbes | Proteobacteria, Firmicutes, Bacteroidetes, Actinobacteria | E. coli, Streptococcus, Bacteroides vulgatus, Bacteroides, Bilidobacterium longum, and Actinobacteria |
| Post-natal             | Gut microbes | Firmicutes, Proteobacteria | Enterococcus, Enterobacter and Klebsiella |
| Post-natal             | Skin and oral microbes | Proteobacteria, Firmicutes, Proteobacteria | Enterobacter, Haemophilus, Staphylococcus saprophyticus, S. aureus, Streptococcus australis, and Veillonella Clostridium difficile, Granulicatella adiacens, Citrobacter spp., Enterobacter cloacae, Bilophila wadsworthia |

| Microbial colonization | Relative abundance | Primary outcome and influence on immune functions | Reference |
|------------------------|--------------------|--------------------------------------------------|-----------|
| Pre-natal              | Observed in the fetus during the pre-natal period | • Identification of natural bacterial flora in the fetus confirms the microbial exposure and colonization of fetal organs during the pre-natal period  
• The presence of fetal memory T cells during the pre-natal period indicates microbial priming of an adaptive immune response even before birth | Mishra et al. [117] |
| Pre-natal              | Identified in the umbilical cord blood | • Mother-to-child transmission of healthy microbes during the pre-natal period may boost the neonatal immune functions via the production of short chain fatty acids and may also reduce their susceptibility to acquire undesired pathogens that could be acquired from the hospital environment | Jimenez et al. [108] |
| Pre-natal              | Identified in the placenta | • Placenta harbors a unique microbiome; despite its low abundance, it is metabolically active. However, their influences on the immune function are not discussed | Aagaard et al. [110] |
| Pre-natal              | Identified in placenta and fetal lungs | • Fetal lungs and placenta harbor a microbial signature, which could possibly be transplacentally derived and acquired in utero; however, their influences on immune function are not discussed | Al Alam et al. [111] |
| Microbial colonization | Relative abundance | Primary outcome and influence on immune functions | Reference |
|-----------------------|-------------------|-----------------------------------------------|------------|
| Pre-natal             | Identified in the fetal intestines | • Fetal intestines harbor a unique microbial signature, which can influence the fetal immune system as early as the first trimester  
• The presence of *Micrococcus* in the fetal intestines can modulate mucosal immunity and may predispose fetal T cells to develop into regulatory T cells  
• Fetal intestinal flora dominated by Micrococcus can mount an inflammatory response by inducing tolerogenic APCs and inhibiting IFN-γ production by fetal memory T cells  
• Fetal intestinal flora dominated by Micrococcus can mount an inflammatory response by inducing tolerogenic APCs and inhibiting IFN-γ production by fetal memory T cells and exhibiting higher PLZF + CD161 + T cell proportion in lamina propria to promote epithelial stem cell function and distinct programs of immune cell recruitment | Rackaityte et al. [112] |
| Post-natal            | Increase in abundance in vaginally delivered neonates | • Natural microbial inoculation during vaginal delivery induces better immune functions in neonates such as lipopolysaccharide (LPS) biosynthesis pathways and two-component systems pathways compared to babies born via a C-section | Wampach et al. [119] |
|                       | Increase in abundance in C-section delivered neonates | • LPS can prime the neonatal immune system by stimulating the pro-inflammatory cytokines | Ferretti et al. [120] |
|                       | Increase in abundance in neonates delivered via C-section | • Vertical mother-to-infant microbial transmission occurred through multiple sources during pre- and post-natal | |
| Post-natal            | Increase in abundance in formula-fed infants | • Opportunistic pathogens that tend to be found in hospitals are dominated in babies born by C-section. Genome-wide sequencing indicates that these bacteria contain genes responsible for antibiotic resistance and virulence  
• Babies born by C-section have an increased risk of asthma and obesity later in life | Shao et al. [124]  
Dominguez-Bello et al. [125]  
Keag et al. [123] |
| Post-natal            | Increase in Gram negative abundance | • The gut flora of babies born by C-section is derived from opportunistic colonization and more similar to the skin and oral flora of the mother or the surrounding environment during delivery  
• The microbiome of infants delivered by C-section tended to contain 90% higher prevalence of antibiotic resistance genes compared to vaginally delivered infants | Backhed et al. [9]  
Bezirtzoglou et al. [126] |
| Post-natal            | Early gut or lung abundance in fetus | • Early exposure to Gram-negative commensal bacteria strongly influences the host immune system and is inversely associated with asthma and allergic sensitization at school age  
• Elevated levels of infant home endotoxin and subsequent reduced Th2 cytokine IL-13 production are associated with a reduced risk of allergic sensitization | Prince et al. [118] |
A recent study described the differential expression of arginase-2 between fetal and adult splenic dendritic cells resulting in the fetal dendritic cells to favor the induction of Treg and Th2 cells over Th1 cells [138]. Human cord blood studies have also shown that neonates have negligible amounts or complete absence of Th17 cells [139] that play significant role in developing immunity against fungal and bacterial infections at epithelial barriers [140]. Tregs and Th17 cells have reciprocal development pathways in the absence of the pro-inflammatory cytokines IL-6, IL-1β, and IL-23 wherein Foxp3 dominates RORγt function and prevents Th17 development. Thus, neonatal immunity is typically considered to exhibit an anti-inflammatory profile as the Th2 and Treg phenotype bias in early life impairs Th1 and Th17 immune responses [141] but may instead lead to a bias towards the development of an atopic phenotype.

Mechanisms of Microbial Effects on Adaptive Immunity

Immuno-Microbiome Interactions Alter T Cell Differentiation in Allergic Diseases

The human body is constantly exposed to an external microbial environment comprised of a wide variety microbial species able to colonize the barrier organs of the human body forming symbiotic, commensal, or pathogenic relationships with the host [142, 143]. During development the immune system co-evolves in the presence of these microbes and plays an important role in maintaining the homeostatic balance between tolerance and allergy, through regulation of host-microbiome interactions. Recently, the influence of the gut microbiota in the development of allergic disease has become widely studied, revealing that during early developmental stages, the immune system becomes tolerized to commensal bacteria, through the induction of a corresponding complement of IgA antibodies and regulatory T cells, enabling the commensal bacteria present to be maintained in the gut over time [35]. Interestingly, it has been shown that compositionally and functionally distinct gut microbiota exist at different stages of neonatal development and exert differential influences on the immune system [32]. During development, gut microbial dysbiosis may occur which can alter the homeostatic balance of the immune system leading to a cascade of events that results in an allergic outcome [78]. Animal-based studies have identified the presence of at least two distinct types of Tregs in the gastrointestinal tract — thymically-derived Treg (tTreg) and peripherally induced Treg (pTreg), the latter being predominantly enriched in the intestines and largely responsible for maintaining tolerance to food and microbiota-derived antigens at mucosal surfaces [144], with the composition of the gut microbiome influencing the differentiation of pTregs.
in an antigen-specific manner [145]. Germ-free animal studies indicate that pTregs fail to differentiate in the gastrointestinal tract of mice lacking a diverse microbiota, whereas a normal tTreg compartment was maintained in these animals [144]. Furthermore, it has been reported that dietary antigens can induce the differentiation of pTregs, with this population being distinct from the microbiome-induced pTregs, in that they co-express both Foxp3 and GATA3, have a limited lifespan, and can repress the strong immunity to ingested protein antigens [146]. Although most of these studies have been conducted in animal models, recent clinical studies on human subjects identified that Tregs are not functionally impaired in individuals with allergies, but there is a striking increase in the proportion of reactive Th2 cells in these individuals [147], indicating that antigen escape from Treg control was the dominant factor associated with the loss of tolerance observed in allergic individuals.

**Th2/Treg Axis and the Microbiome**

Under homeostatic conditions, the adaptive immune system normally develops a system of tolerance to harmless environmental antigens largely mediated by members of the T cell lineage, particularly Treg cells [147]. Tregs play a dual role in the intestine, by maintaining immune tolerance to dietary antigens [148] and limiting the potentially damaging immune responses that can be generated against environmental pathogens [149]. However, when there is a failure in generation of tolerance by Treg cells against common food and aero-antigens, it can result in the differentiation of allergen-specific cells of the Th2 lineage and the associated production of atopy-inducing IgE [150]. Along with a cascade of downstream events triggered by production of cytokines including IL-4, IL-5, IL-9, and IL-13, ultimately leading to the recruitment and activation of a raft of innate immune cells including basophils, eosinophils, ILC2’s, and M2 macrophages, which together cause the pathology associated with allergic disease [151]. A subset of human memory Th2 cells, allergen specific Th2 cells have been recently reported to be confined only to atopic individuals, referred to as Th2A cells. These Th2A cells are terminally differentiated and co-express CRTh2, CD49d, and CD161 and are thought to be functionally distinct from conventional Th2 cells [152], as they may be more readily activated by perturbations in mucosal barrier function and activation by the “alarmin” cytokines TSLP, IL-25, and IL-33 [153]. Treg cells, on the other hand, produce the anti-inflammatory cytokines, TGFβ, and IL-10, which among other regulatory mechanisms are key in protecting the host from excessive inflammatory immune responses [154]. Hence, a balance in the Th2/Treg axis is essential to protect against the development of allergic disease [155]. Studies in animal and human systems have begun to elucidate several potential mechanisms that tie the microbiome and microbial diversity to alterations in the regulation of Th2 and Treg differentiation leading to a cellular and molecular rationale for those observations made by the hygiene hypothesis. Intriguingly, studies of germ-free mice lacking a microbiome found that a complete microbial dysbiosis led to the establishment of a default Th2 biased immune environment [156, 157], reminiscent of that observed during neonatal and early post-natal life [134, 135, 138]. Indicating that the introduction of commensal bacteria at an early stage may be critical for ensuring normal cellular maturation and recruitment in order to control allergic inflammation. Studies into the relative roles of tTreg and pTreg cells revealed that animals deficient for pTreg had altered ratios of Firmicutes to Bacteroidetes, which was associated with the spontaneous induction of Th2-associated mucosal inflammation and lung pathology [158]. Revealing that pTreg are essential for regulation of the homeostatically controlled microbial community in the gut, through exerting control over Th2 mucosal inflammation and regulating the induction of Th17 differentiation which enables B cell production of IgA and the establishment of a “mucosal firewall” [159]. A key component of this microbial regulation of type 2 inflammation was shown to be induced through the induction of intestinal RORyt+ pTregs, which modulate the differentiation of Th2 cells in a CTLA-4-dependent manner by regulating the co-activator functions of stimulatory DC [160], thereby balancing immune responses at the mucosal surface through the induction of Th17 and Treg cells [145].

**Effects of Microbial Products on T Cell Immune Responses**

Multiple studies have now shown that specific products of metabolism synthesized by the component species of the microbiome are able to exert effects on the differentiation and function of CD4+ T cells [161], providing a mechanistic rationale that directly links microbial dysbiosis with the alterations in immune function that lead to allergic disease (Table 3). Some of the earliest studies linking microbial metabolites with alterations in immune function focused on the effects of antibiotics on disrupting microbial homeostasis, as the use of antibiotics at an early age is a known risk factor associated with increased risk for atopy [161]. Murine models have revealed that along with the induction of a microbial dysbiosis, antibiotic treatment also caused a concomitant decrease in protective gut Treg cells and the induction of inflammation. Intriguingly, this decrease in Treg cells and the associated inflammatory response could be inhibited by treatment with SCFA [162] (Fig. 2). Under homeostatic conditions, SCFA are produced by the microbial conversion of dietary fiber by anaerobic fermentation [163], especially by those microbial taxa associated with protection, including Clostridia and Firmicutes.
Generation of protective intestinal pTreg can be driven by SCFAs including butyrate [145] and propionate [160] in conjunction with bacterial antigens [164]. Generation of the type 2 response suppressing RORγt + Tregs was found to be largely dependent on the presence of SCFA butyrate [61, 165], providing an intriguing molecular post-biotic link between the microbiome and regulation of inflammation. Butyrate has also been shown to play a distinct role in the regulation of type 2 innate lymphoid cells (ILC2s), which are associated with the induction and exacerbation of asthma. Here, butyrate was found to alter HDAC2 activity inhibiting GATA3 expression and ILC2 proliferation [166]. It should be noted that whilst SCFAs contribute to mucosal immune homeostasis, excessive or suboptimal levels of SCFAs have been reported to be associated with inflammation and cancer [167]. The microbiome has also been observed to modify a range of host-derived molecules into steroidal compounds with de novo biological activities and immune functionality [160].

Bile acids which usually aid in the emulsification of dietary fats can also undergo bacterial transformation in the colon into the secondary bile acid 3β-hydroxydeoxycholic acid, which in turn can modulate DC function and facilitate the differentiation of, and increase in the levels of RORγt + pTregs present in the intestinal mucosa [168] that are key for regulating the onset of spontaneous type 2 inflammation [169]. The activation of DC by microbial polysaccharides acting through Toll like receptor-2 (TLR2) signaling has also been demonstrated to play an anti-inflammatory role in the intestine via the induction of Treg and an increase in local IL-10 production [170, 171]. The importance of the B vitamins folate (B9) [172] and niacin (B3) [173] in the maintenance and regulation of function in the intestinal Treg compartment has previously been described, along with studies linking folate with both protective effects against asthma [174] and increased rates of food allergy [175]. Hence, future studies are needed to confirm the direct mechanistic action of these metabolites in the context of allergic disease.

### Table 3 Effects of microbial products on T cell immune responses

| Metabolic product       | Microbial source                  | CD4+T cell effects                                      | Mechanism                                                                                     | Reference |
|-------------------------|-----------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------|
| Short Chain Fatty Acids | Clostridia Firmicutes             | Enhanced generation of intestinal pTreg                | Increased levels of TGFβ through activation of enhanced secretion by epithelial cells          | [57, 61, 145, 160, 163, 164] |
| Butyrate                | Clostridia Firmicutes             | Induction of Treg differentiation                      | Enhanced histone acetylation at promoter and CNS1 & 3 sequence regions of the Foxp3 locus       | [61]      |
| Propionate              | Clostridia Firmicutes             | Enhances Treg differentiation                          | Binds to CD4+ T cell receptor GPR43, to reduce histone deacetylase activity (HDAC6 and HDAC9) | [163]     |
| Bile acids              | Commensal Bacteria                | Induction of colonic RORγt-expressing Treg cells       | Signals via farnesoid X receptor (FXR) to induce Tregs in a CNS1 dependent manner              | [167]     |
| Microbial polysaccharides | *B. bifidum*, *B. fragilis*      | Induction of Treg differentiation                      | Acts via Toll like receptor-2 signaling pathway in peripheral dendritic cells                   | [170, 171] |
| Folate (Vitamin B9)     | *Bifidobacterium*, *Lactobacillus*| Promotes survival and maintenance of Treg              | Enhanced expression of anti-apoptotic Bcl2 in Treg cells                                       | [172]     |
| Niacin (Vitamin B3)     | Commensal bacteria                | Enhances Treg differentiation and IL-10 production     | Activation of Gpr109a niacin receptor to induce IL-10 expression in antigen presenting cells   | [173]     |
| Indole-3-lactic acid (IDO) | *L. reuteri*, *B. infantis*       | Silence both Th2 and Th17 cells effector function      | Signaling through AhR expressed on CD4+ to upregulate Galectin-1                               | [177, 178] |
| 12,13-diHOME            | *E. faecalis*, *B. bifidum*       | Increased Th2 differentiation and IL-4 production      | Acts directly on CD4+ T cells and exerts effects on PPARγ signaling in dendritic cells        | [168, 169] |
Colonization of the gut with \textit{L. reuteri} was previously shown to induce protective Treg cells in an allergic airway mouse model \cite{176}. More recently, studies have indicated that a tryptophan metabolite Indole-3-lactic acid (IDO) produced by both \textit{L. reuteri} \cite{177} and \textit{B. infantis} were able to silence both Th2 and Th17 cells through upregulation of galectin-1, demonstrated in human studies \cite{178}.

In a longitudinal study focused on multisensitised atopic children, it was determined that alterations in the gut microbiome and in metabolic activity were evident as early as 3 months of age, during which a distinct fecal microbiome and metabolome were present in those children who went on to develop atopy at 3 years of age. Fecal metabolite extracts isolated from these subjects induced an increase in the relative proportion of IL-4 expressing Th2 cells, whilst also exhibiting Treg suppressive capabilities \cite{168}. Subsequently, one of the compounds identified in this study, 12,13-diHOME a linoleic acid metabolite, was shown to exacerbate lung inflammation in mice and elevated levels of the compound were detectable in neonatal children at 1 month of age, who later went on to develop atopy by age two \cite{169}, providing further evidence of the importance of the gut microbiota and the microbial products that it produces in conditioning of the immune system at an early time in life.

\section*{Microbial Dysbiosis and the Development of Allergic Diseases}

\subsection*{The Hygiene Hypothesis}

The “hygiene hypothesis” concept dates back to a longitudinal study published by Strachan in 1989 \cite{179} and was initially put forward as an explanation for the emergence of hay fever as a “post-industrial revolution epidemic.” The data published in Strachan’s study established a correlation between hay fever and house size and noted that as the number of older children in the house rose, the incidence of hay fever in younger siblings decreased, leading to the hypothesis that allergic diseases may be associated with a lack of early childhood exposure to infectious disease, spread by unhygienic interactions with older children. Hence, a general decrease in family size and increase in personal cleanliness, along with a concomitant decrease in exposure to Th1 skewing infections during early childhood caused the increased rates of atopic disease \cite{180}. This initial correlation between rates of early childhood infection with the incidence of atopy was subsequently assessed more directly in multiple studies. An analysis of herpes simplex virus infection rates during the first 3 years of life...
life indicated that infection was protective against asthma [181] and a Brazilian study indicated that higher infectious burdens during early life, as measured by plasma Ig levels for exposure to multiple pathogens including herpes simplex virus, Epstein-Barr virus, *Toxoplasma gondii* and *Helicobacter pylori*, correlated with lower levels of atopy [182]. Additional studies of tuberculosis infection [180], varicella infection [183], and BCG vaccination [183] also found an association with lower rates of atopic disease. These findings indicate that early life exposures to bacterial and viral infections and the production of a strong Th1 response were important in promoting a protective environmental milieu that skews the immune system away from the development of an atopic disease inducing Th2-biased system (Fig. 3).

However, several arguments against this Th1-Th2 cytokine shift paradigm have emerged. Large-scale and longitudinal cohort studies from the UK [184], Denmark [185], and Finland [186] concluded that after adjustment for clinically apparent infectious diseases, a protective effect of number of siblings, day care, pet ownership, and farm residence was instead responsible for the decreased odds ratios observed (Table 4). Additionally, as atopic disease rates have increased, a concomitant rise in cases of autoimmune diseases has also been observed in children. Including diabetes mellitus (T1D), Crohn’s disease, and multiple sclerosis [187]. As these diseases are largely dominated by Th1 and/or Th17 responses [188], it seems unlikely that the Th1-Th2 cytokine shift paradigm is robust enough to explain the increased development of both sets of disease. Especially in light of findings that indicate there may in fact be an association between the incidence of allergic and autoimmune diseases [189–191]. Furthermore, a large-scale retrospective cohort study (1990–2018) conducted in the UK concluded that the long-term risks of autoimmune disorders are significantly higher in patients with allergic diseases [192]. A recent meta-analysis of the commonalities in 290 genetic loci previously associated with 16 autoimmune diseases, found a significant enrichment of multiple loci also associated with allergy, suggesting that a further investigation of shared mechanisms may help in understanding the complex relationship between these disease syndromes [193]. Contrary to what might have been predicted by the Th1-Th2 cytokine shift paradigm, infections with helminths result

![Fig. 3 Cellular Basis for Hygiene Hypothesis and Old Friends/Biodiversity models. A The original hygiene hypothesis focused on an absence of a sufficient viral/bacterial pathogenic burden to educate the immune system in childhood, allowing for the induction of an aberrant Th2 response. Mechanistically this was seen due an imbalance in the reciprocal regulatory relationship that exists between Th1 and Th2 responses mediated by IL-4 and IFN-γ. B Old friends/biodiversity hypotheses’ additionally factors in the presence of regulatory mechanisms that are essential for control of both autoimmune and allergic responses and are associated with the presence of a diverse microbiome. Here, the lack of sufficient regulatory responses accounts for the parallel rise in both autoimmune disease (Th1) and allergy (Th2) seen in recent history.](image-url)
in a Th2-polarized immune response including production of IL-4, IL-5, IL-13, eosinophilia, and high serum titers of IgE, all hallmarks of allergic disease. Whilst at the same time, helminthic infections have largely been associated with inducing protective effects on the development of atopic disease as well as naturally occurring infection with *Trichuris trichiura*, *Enterobius vermicularis*, and *Schistosoma mansoni*, which have all been shown to exhibit a protective effect [194], especially when exposure was found to occur during in utero development [195] or early in life [196, 197]. However, the protective effects of helminths do not appear to be universal, for example, infection with *Ascaris lumbricoides* or *S. mansoni* has also been associated with higher asthma rates in certain populations [198–200].

### Table 4 Summary of studies showing associations between environmental factors linked to the hygiene hypothesis and atopic disease

| Environmental factor                | Effect on atopic disease risk | Cellular response | Inflammatory response | Antibody response | Reference |
|-------------------------------------|-------------------------------|-------------------|-----------------------|-------------------|-----------|
| **Decreased family size**           |                               |                   |                       |                   |           |
| ↑ Allergic rhinitis                 | –                             | –                 | –                     | –                 | Strachan [179] |
| ↑ Allergic rhinitis                 | –                             | –                 | –                     | –                 | Genuniet al. [26] |
| ↑ Atopic dermatitis                 | –                             | –                 | –                     | –                 | Benn al. [185] |
| **Infectious disease**              |                               |                   |                       |                   |           |
| - Tuberculosis                      | ↓ Asthma                       | ↑ Th1             | ↑ IFNγ ↓ IL4, IL5     | ↓ IgE             | Shirakawa et al. [180] |
| - HSV                               | ↓ Asthma                       | –                 | –                     | ↓ IgE             | Illi et al. [181] |
| - HSV, EBV, T. gondi                | ↓ Atopy                        | ↓ Th2 ↓ Treg      | ↓ IL5 IL13 IL10      | ↓ IgE             | Figueiredo et al. [182] |
| & H. pylori, Varicella              |                               |                   |                       |                   |           |
| - Infection history (30 Infections) | No associated risk             | –                 | –                     | –                 |           |
| - Infection history (<6 months)     | No associated risk             | –                 | –                     | –                 |           |
| - Infection history (Respiratory/Enteric) | No associated risk | –                 | –                     | –                 |           |
| **Parasitic Infection**             |                               |                   |                       |                   |           |
| - T. trichiura                      | ↓ Skin reactivity              | –                 | –                     | –                 | Rodrigues al. [234] |
| - A. lumbricoides                   | ↓ Atopic dermatitis            | –                 | –                     | ↑ IgE IgG4        | Cooper et al. [196] |
| - S. mansoni                        | ↑ Asthma                       | –                 | –                     | –                 | Leonardi-Bee et al. [198] |
| - N. americanus                     | ↓ Atopic dermatitis            | –                 | –                     | ↑ IgE sIgE        | Araujo et al. [200] |
| - Maternal helminth infection       | ↑ Asthma                       | –                 | –                     | –                 | Leonardi-Bee et al. [198] |
| - Anthelminthic usage (Ivermectin)  | ↓ Eczema                       | –                 | –                     | –                 | Elliot et al. [195] |
|                                    | ↑ Eczema                       | –                 | –                     | –                 | Endara et al. [197] |
| **Farm residence**                  |                               |                   |                       |                   |           |
| ↓ Atopic dermatitis                 | –                             | –                 | –                     | –                 | Benn et al. [185] |
| ↓ Allergic rhinitis                 | –                             | –                 | –                     | –                 | Genuniet al. [26] |
| ↓ Atopic dermatitis                 | ↑ Treg ↓ Th2                  | ↓ IL4 IL5 IL13    | ↓ IgE                 | –                 | von Mutius and Vercelli [92] |
|                                    |                               |                   |                       |                   |           |
| **Pet ownership**                   |                               |                   |                       |                   |           |
| ↓ Atopic dermatitis                 | –                             | –                 | –                     | –                 | Benn et al. [185] |
| **Day care**                        |                               |                   |                       |                   |           |
| ↓ Atopic dermatitis                 | –                             | –                 | –                     | –                 | Benn et al. [185] |
| No associated risk                  | –                             | –                 | –                     | –                 | Dunder et al. [186] |
| **Breast milk vs. formula feeding** |                               |                   |                       |                   |           |
| ↓ Asthma ↓ eczema                   | –                             | –                 | –                     | –                 | Heine [10] |
| ↓ Asthma ↓ eczema                   | –                             | –                 | –                     | –                 | Oddy [11] |
| ↓ Food allergy                     | –                             | –                 | –                     | –                 | Wang et al. [12] |
| **Antibiotic usage during infancy** |                               |                   |                       |                   |           |
| ↑ Asthma                            | –                             | –                 | –                     | –                 | Pitter et al. [17] |
| ↑ Asthma                            | –                             | –                 | –                     | –                 | Slob et al. [16] |
| ↑ Asthma                            | –                             | –                 | –                     | –                 | Yassour et al. [15] |
| **Delivery by Cesarean birth**      |                               |                   |                       |                   |           |
| ↑ Asthma                            | –                             | –                 | –                     | –                 | Lin et al. [19] |
| No associated risk                  | –                             | –                 | –                     | –                 | Juhn et al. [20] |
Although, the “hygiene hypothesis” has been widely accepted by both the scientific community and the general public, it is not without its limitations. Care needs to be taken in terms of interpreting the message when associating hygiene with the pathogenesis of atopic disease [201]. The hygiene hypothesis has however been pivotal in framing the idea that the immune system is still relatively naïve at birth and whilst the adaptive immune system has gone through an internal developmental process to largely limit the number of cells present capable of mounting a response against self, it still needs to be “fed” with information about how to interpret antigens present in the local environmental. Recent studies indicate that this process may largely occur within the first few months following birth through constant contact with microbes from the external environment, as well as via transfer from other humans, especially from close maternal contact. When such microbial exposure is inadequate, the mechanisms regulating the immune system can fail, resulting in autoimmune and allergic diseases [202].

Current Perspectives

The “old friends” hypothesis, put forward by Rook in 2003 [203], and the “biodiversity hypothesis” of allergy proposed by Haataela [204] have subsequently emerged, both of which postulate a similar theme that the emergence of allergic reactions is an outcome of a lack of symbiotic relationships with parasites, viruses, and bacteria which have been beneficial for evolution in the past [205]. These hypotheses are also sometimes referred to as “Western lifestyle hypotheses.” The western lifestyle is being generally characterized by minimal or no physical activity among children with most of the time being spent indoors leading to obesity among children and also exposure to increased allergic burdens, especially those found indoors, including house dust mites (HDMs) [205], thereby leading to a massive shift in the human disease spectrum from infectious diseases to allergies. In addition, excessive use of antibiotics, with an average of approximately 2.5 antibiotic doses per 100 people/day in Western countries [206], and increased use of sanitation technologies have resulted in elimination of certain eukaryotic symbionts, including helminths and protists from the human gut ecosystems [207]. Taken together, these environmental factors associated with westernized lifestyle trigger dysbiosis by affecting intestinal epithelial cell metabolism, sequestering nutrient sources [208], and creating a favorable environment for facultative anaerobes—such as pathogenic Escherichia coli and Salmonella [209, 210] at the expense of symbiotic flora such as Bacteroides, Prevotella, Desulfovibrio, and Lactobacillus [211, 212]. The microbial dysbiosis induced by a westernized diet or lifestyle may also result in a leaky mucosa and reduced intestinal production of short chain fatty acids (SCFAs) [213]. A prolonged microbial dysbiosis may lead to leakage of pathogen-associated molecular patterns (PAMPs), including LPS, in the blood, and trigger low-grade inflammation or allergy [213, 214], ultimately resulting in a change in the lung, gut, and skin microbiomes causing microbial dysbiosis which leads to a sharp decrease in infectious diseases and a higher prevalence of allergies (Fig. 3).

“Unhygienic Therapies” for Atopic Diseases

As the “hygiene hypothesis” postulates that a lack of microbial interactions in early life leads to an increased risk of atopic disease, the reverse correlate of this implies that the introduction of microbes or use of “unhygienic therapies” may be beneficial in restoring the missing constituents of microbial communities for either treatment or prevention of disease (Tables 5, 6, and 7). The treatment of immunocompromised patients suffering from recurrent Clostridium difficile infections has demonstrated the amazing utility of fecal microbiota transplants, where fecal transplant has revolutionized the management of disease leading to a cure rate of 90% after treatment [215]. Although there have been limited studies to date, looking at the use of fecal transplant for treatment of allergic disease in humans [216], a recent study has demonstrated that the transfer of fecal material from healthy infants into a germ-free mouse model was protective against an anaphylactic response to cow milk allergens, whereas colonization of the murine gut with the microbiome from cow’s milk allergic infants was unable to confer protection [217]. Additionally, the transfer of the skin microbiome has become a recent area of interest with the topical microbiome transplantation of R. mucosa demonstrating efficacy for treatment of both pediatric and adult atopic dermatitis [218] and more recently, the use of bacteriotherapy was shown to decrease the incidence of S. aureus in AD patients [219]. Whilst these studies do provide hope for use of microbial treatment for allergic disease, a large number of studies have examined the possibility of using probiotic supplementation to either prevent or treat disease (Table 1). The majority of probiotic studies into food allergy and atopic dermatitis have investigated administration of either a single or the combination of a limited number of bacterial species and have been shown to have limited utility in either preventing or treating allergic disease [220–228]. Probiotic intervention strategies have also been widely trialed as a potential prophylactic therapy for asthma both during pregnancy [229] or during infancy [230–232]. However, the meta-analysis of these studies has not revealed any substantial protective benefits which could be derived from the current probiotic therapies trialed.

Exposure to infections with helminthic nematodes is also largely absent in industrialized societies, raising the prospect for an additional therapeutic avenue to be explored. Parasitic worms or compounds from their excretory/secretory milieu
| Allergic condition                  | Microbial treatment                                                                 | Study outline                                                                                                                                                                                                 | Follow up period |
|------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Peanut Allergy                     | *Lactobacillus rhamnosus*                                                            | 62 pediatric subjects (ages 1–10) double-blind, placebo-controlled randomized trial of the probiotic *Lactobacillus rhamnosus* and peanut oral immunotherapy (PPOIT). Analyzed unresponsiveness at 2 and 5 wks. Following treatment. (NB: No OIT without PP arm was included.) | 2 years          |
| Cow milk allergy                   | *Lactobacillus casei* and *Bifidobacterium lactis*                                    | 119 infants with CMA took part in a double-blind, randomized, placebo-controlled trial. Received CRL431 and Bb-12 supplement added to a standard treatment of extensively hydrolyzed formula for 12 months | 6 months and 12 months |
| Cow Milk Allergy                   | *Lactobacillus GG*                                                                   | 80 infants with CMA took part in a double-blind, randomized, placebo-controlled trial. Group 1 received extensively hydrolyzed casein formula (EHCF), group 2 received ECHF + *Lactobacillus GG* for 12 months | 18 months        |
| Cow Milk Allergy (Non-IgE)         | *Bifidobacterium breve*                                                               | A total of 35 (test) and 36 (control) subjects were randomized and received test or control formula for 8 weeks. Test formula was a hypoallergenic, nutritionally complete AAF including a prebiotic blend of fructo-oligosaccharides and the probiotic strain *Bifidobacterium breve* M-16 V. Control formula was AAF without symbiotic | 8 weeks          |
| Atopic dermatitis                  | *Lactobacillus rhamnosus* or *Bifidobacterium animalis*                               | 425 infants from a high-risk birth cohort participated. Maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation until 2 years with either *Lactobacillus rhamnosus* or *Bifidobacterium animalis* | 4 years          |
| Atopic Dermatitis                  | *Lactobacillus GG*                                                                   | 250 pregnant women carrying infants at high risk of allergic disease were recruited to a randomized controlled trial of probiotic supplementation (*Lactobacillus GG*) from 36 weeks gestation until delivery. Infants were then assessed during their first year for eczema or allergic sensitization | 1 year           |
| Atopic Dermatitis                  | *Roseomonas mucosa*                                                                  | 10 adult and 5 pediatric patients were enrolled in an open-label phase I/II safety and activity trial for *R. mucosa* transplantation. Patients self-administered topical bacteria over a 4 or 6 wk. period, results were assessed at 12 wk | 4 months         |
| Atopic Dermatitis                  | *Lactobacillus GG*                                                                   | 132 high risk pregnant women took part in a double-blind, randomized placebo-controlled trial. *Lactobacillus GG* was administered prenatally to mothers and postnatally for 6 months to their infants | 2 years          |
| Atopic Dermatitis                  | *Lactobacillus rhamnosus* *GG*, *L. acidophilus* *La-5* and *Bifidobacterium animalis subsp. lactis Bb-12* | 415 pregnant women participated in a randomized, double-blind trial of children from a nonelected maternal population. Women received probiotic milk or placebo from 36 weeks of gestation to 3 months postnatally during breastfeeding | 2 years          |
Table 5 (continued)

| Allergic condition                  | Microbial treatment                                                                 | Study outline                                                                                                                   | Follow up period       |
|-------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------|
| Atopic dermatitis rhino-conjunctivitis | *L. rhamnosus* LC705, *Bifidobacterium breve Bb99* and *Propionibacterium freudenreichii ssp. shermanii JS* | 1223 mothers were recruited during pregnancy and randomized at 35 weeks of gestation to the probiotic or placebo group. Mothers twice daily received one capsule containing a mixture of probiotics or placebo. Their infants were given the same capsules opened and mixed with galacto-oligosaccharides syrup (prebiotics) once daily from birth, continuing to 6 months after birth | 5 years and 10 years |

| Allergic condition    | Study outcomes                                                                 | Reference                                      |
|-----------------------|-------------------------------------------------------------------------------|-----------------------------------------------|
| Peanut Allergy        | Possible sustained unresponsiveness was achieved in 82.1% receiving PPOIT and 3.6% receiving placebo (*P* < .001). PPOIT was associated with reduced peanut skin prick test responses and peanut-specific IgE levels and increased peanut-specific IgG4 levels | Tang et al. [220] |
| Cow milk allergy      | No significant difference in tolerance to cow milk at 6 and 12 months was found with: 77% tolerance in the probiotics group compared to 81% in the placebo group | Hol et al. [221] |
| Cow Milk Allergy      | Infants in group 2 had a higher probability of acquiring tolerance at 6 and 12 months compared with subjects in group 1. In infants with IgE mediated CMA SPT responses decreased in both groups after 6 and 12 months, although the difference was not significant | Berni Canani et al. [222] |
| Cow Milk Allergy (Non-IgE) | At week 8 participants showed statistically significant differences (*P* < 0.001) between test and control groups in the fecal composition of Bifidobacteria and ER/CC. Analyses of clinical outcomes revealed no statistically significant differences were observed at week 8 | Candy et al. [223] |
| Atopic dermatitis     | Prevalence of eczema by 4 years and prevalence of rhinoconjunctivitis at 4 years were significantly reduced in the children taking *L. rhamnosus*. There were also non-significant reductions in the cumulative prevalence of wheeze and atopic sensitization. *B. animalis* did not affect the prevalence of any outcome | Wickens et al. [224] |
| Atopic Dermatitis     | Prenatal probiotic treatment was not associated with any change in cord blood immune markers. Prenatal treatment with *Lactobacillus* GG was not sufficient for preventing eczema | Boyle et al. [225] |
| Atopic Dermatitis     | *R. mucosa* treatment was associated with a significant decrease in measures of disease severity, including pruritis, topical steroid requirement, and S. aureus burden | Myles et al. [218] |
| Atopic Dermatitis     | The prevalence of eczema in the treated group was significantly reduced at 2 years of age compared to placebo, (15/64 [23%] vs 31/68 [46%]). Lactobacillus GG was effective in prevention of early atopic disease in children at high risk | Kalliomaki et al. [226] |
| Atopic Dermatitis     | Probiotics administered to nonelected mothers reduced the cumulative incidence of AD, with a reduced OR of 0.51 at 2 years of age, but had no effect on atopic sensitization | Dotterud et al. [227] |
| Atopic dermatitis rhino-conjunctivitis | Perinatal probiotics decreased eczema up to 10 years of age (35.2% vs 41.7%, adjusted OR: 0.74; 95% CI: 0.55–1.00; *P* < .05), but at 5–10 years, allergic rhino-conjunctivitis was increased (33.2% vs 26.3%, OR: 1.39; 95% CI: 1.03–1.89; *P* = .03) | Peldan et al. [228] |
Table 6  Therapeutic approaches to treatment of allergic disease with microbes and microbial products: meta-analyses of microbial treatment strategies for allergic diseases

| Allergic condition                      | Meta-analysis summary                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                                     | Recommendations                                                                                                                                                                                                         | Reference       |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Asthma, wheeze                          | 20 eligible trials identified including 4866 children. Heterogeneous in the type and duration of probiotic supplementation, and duration of follow-up. Five trials conducted follow-up beyond participants' age of 6 years with a median of 24 months, none were powered to detect asthma as the primary outcome | No evidence to support a protective association between perinatal use of probiotics and doctor diagnosed asthma or childhood wheeze. Randomized controlled trials to date have not yielded sufficient evidence to recommend probiotics for the primary prevention of these disorders | Extended follow-up of existing trials, along with further clinical and basic research, are needed to accurately define the role of probiotics in the prevention of childhood asthma | Azad et al. [229] |
| Atopic dermatitis, asthma, allergic rhinitis, wheeze | 17 eligible studies identified. Heterogenous in type, duration and conditions assessed. Reporting data from 4755 children (2381 in the probiotic group and 2374 in the control group), were included in the meta-analysis | Infants treated with probiotics had a significantly lower risk ratio for atopic dermatitis compared to controls especially those administered a mixture of probiotic supplements. No significant difference in terms of prevention of asthma, wheezing or rhino conjunctivitis was determined | Results of the meta-analysis show probiotic supplementation can aid in preventing infantile eczema, suggesting a new potential indication for probiotic use in pregnancy and infancy | Zuccotti et al. [230] |
| Asthma, wheeze                          | 19 eligible studies were identified. Randomized trials involving reporting data from 5157 children fulfilled the inclusion criteria. Trials were heterogenous in type and duration of probiotic supplementation administered | There was no significant association of probiotics with risk of asthma or wheeze compared with placebo. Subgroup analysis by asthma risk indicated that probiotics significantly reduced wheeze incidence among infants with coincident atopic disease | Probiotic supplementation compared with placebo groups did not show an association with a lower risk of asthma in infants. The findings reported here do not support a recommendation of probiotics use in the prevention of asthma in infants | Wei et al. [231] |
| Asthma, wheeze, eczema                  | Assessed 21 randomized controlled trials via systematic review and metanalysis where appropriate                                                                                                                        | Assessed evidence did not indicate that probiotic supplementation significantly reduces the risk of children developing allergy. Considering all critical outcomes, the WAO guideline panel determined that there is a likely net benefit from using probiotics resulting primarily from prevention of eczema | WAO guideline panel suggests: a) using probiotics in pregnant women at high risk for having an allergic child; b) using probiotics in women who breastfeed infants at high risk of developing allergy; and c) using probiotics in infants at high risk of developing allergy. All recommendations are conditional and supported by very low-quality evidence | Fiocchi et al. [232] |
Table 7  Therapeutic approaches to treatment of allergic disease with microbes and microbial products: studies investigating the utility of helminth therapy on allergic disease outcomes

| Allergic condition | Microbial treatment | Study outline | Follow up period | Study outcomes | Reference |
|--------------------|---------------------|---------------|------------------|----------------|-----------|
| Asthma             | *Necator americanus* | Thirty-two individuals with asthma and measurable airway responsiveness were randomized and double blinded to cutaneous administration of ten *N. americanus* larvae, or histamine solution (placebo), and followed for 16 weeks | 16 weeks | Mean airway hyperresponsiveness improved in both groups, hookworm [1.49 doubling doses (DD)], placebo group (0.98 DD), difference between groups was not significant (0.51 DD; 95% confidence interval: -1.79 to 2.80; P = 0.65) | Feary et al. [237] |
| Allergic rhinoconjunctivitis | *Necator americanus* | Thirty individuals with allergic rhinoconjunctivitis and measurable airway responsiveness were randomized, double-blind to cutaneous administration of either 10 hookworm larvae or histamine placebo, and followed for 12 weeks | 12 weeks | There were no significant differences in peak-flow variability, rhinoconjunctivitis symptoms or skin test responses between groups | Feary et al. [236] |
| Allergic rhinitis   | *Trichuris suis*     | 100 subjects grass pollen-induced allergic rhinitis randomly administered 8 doses of 2500 live *T. suis* ova or placebo with an interval of 21 days over 24 wks | 6 months | No significant change in symptom scores, well days, total histamine, grass-specific IgE, or diameter of wheal reaction on skin prick testing with grass or other allergens tested | Bager et al. [238] |
| Peanut or tree nut allergy | *Trichuris suis* | 18 patients with *T. suis* 100—2500 ova orally (dependent on subject age), six doses total with an interval of 14 days over 12 wks | No significant results were reported. There was no change in skin prick test reactivity, except in 1 subject who had a general decrease in reactivity and lost reactivity to peanut | Jouvin and Kinet [239] |
could potentially play a role in mediating tolerance induction either by affecting the composition of organ specific microbiomes or through direct action on the immune system [233]. Infection during early life (0–5 years) with the human parasite *T. trichiura* has been shown to significantly reduce the incidence of allergy later in life [234], potentially through an early life imprinting of the immune system towards a tolerogenic phenotype, much in the same way that early atopic symptoms can be indicative of initiation of the atopic march. Anecdotal accounts in the news media of individuals self-curing themselves through helminth infections have created much interest in helminthic therapy [233, 235]. However, randomized controlled trials into the efficacy of helminthic treatment for asthma [236], hay fever [237, 238], and nut allergies [239] with either the hook worm *N. americanus* or the whipworm *T. suis* have failed to demonstrate any definitive results. Although, it should be noted that several studies have found success in the use of helminthic therapy for the ongoing treatment of patients suffering from ulcerative colitis [240], indicating that there may indeed be a niche for helminthic therapy in the future of the treatment for allergic disease.

Multiple studies have described that distinct microbial species found to be associated with either the establishment of a tolerogenic or inflammatory atopic state at the barrier organs. However, the use of probiotics either in a prophylactic measure or to treat established atopic disease has proved to be largely ineffective, so far (Table 1). This may be due to a number of factors including the limited number of probiotics used, the lack of specific targeting of probiotics to individual patients, or the inability of the administered probiotic to reach the specific intestinal niche that would be aided by more precise targeting. Fecal transfer therapies especially those administered by colonoscopy have had great success [215], potentially due to the diverse range of bacteria being transferred from healthy individuals, in addition to avoidance of the stomach environment and enabling access to a broader region of the intestinal system. However, it should be noted that bacteriotherapy systems for oral administration are also being developed and are proving to be effective [242]. Studies are currently underway to assess whether these means of treatment will be effective for atopic disease and the results are eagerly anticipated [216]. An additional avenue which may prove highly useful for future therapy is through the engineering of specific functions into agents for bacteriotherapy. An example of this approach was recently demonstrated in an animal model, where a strain of *Bacteroides* engineered to produce the secondary bile acid isodCA was introduced and shown to be a potent inducer of gut-associated pTreg cells [167], which can dampen the immune response and support the metabolic function of the gut microbiota [243]. Together, the combined study of the microbiome and the reciprocal relationship of microbes with the development of the immune system has the broad potential for a better understanding of human health and to increase treatment options for atopic diseases, with the hygiene hypothesis proving integral to this path, by shining an initial light on how the microbial dysbiosis prevalent in industrialized societies has affected the regulation of the tolerance inducing mechanisms required for the maintenance of a homeostatic equilibrium with our external environments.

**Summary**

With the increased incidence of allergic diseases, a better understanding of the developmental events that leads to immune sensitization against otherwise innocuous environment antigens is a key to the development of rational intervention strategies. The hygiene hypothesis, first put forward over 30 years ago, has now been expanded to include the effects of microbial dysbiosis with the aid of next generation sequencing techniques [205], leading to a much more robust view of how early life exposure to a diverse array of microbes is important for the development of the immune system and the establishment of a homeostatic relationship with our environment [204, 241], especially at the key barrier organs associated with atopy, namely the skin, airways, and gut. The initial premise of the hygiene hypothesis, that a reduction in exposure to viral and bacterial infections during childhood was responsible for the induction of default atopic Th2 responses, has now been largely disproven [199, 201, 202]. Instead, studies demonstrating the importance of the microbiome in modulating the cohort of regulatory cells induced during development which establish a tolerogenic environment and mediate suppression of T cells that arise from inflammatory lineages [148] allows for a better explanation of the observations, that is in parallel to the emergence of hay fever as a “post-industrial revolution epidemic” [179] and the rise of the atopic march [6], that we have also seen a significant increase in the incidence of autoimmunity over the same period.

**Acknowledgements** The authors would like to thank Paul D. Thacker for his valuable support during the preparation of this manuscript. Images used in production of figures were provided by Vecteezy.com under their free license agreement.

**Author Contribution** All the authors have drafted the manuscript and revised and approved the final version.

**Funding** Open Access funding provided by the Qatar National Library. This project is financially supported by funds from Sidra Medicine to Dr. Souhaila Al Khodor and to Dr. Nicholas van Panhuys. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Declarations

Conflict of Interest  The authors declare no competing interests.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Draaisma E et al (2015) A multinational study to compare prevalence of atopic dermatitis in the first year of life. Pediatr Allergy Immunol 26(4):359–366
2. Mallol J et al (2016) Prevalence, severity, and treatment of recurrent wheezing during the first year of life: a cross-sectional study of 12,405 Latin American infants. Allergy Asthma Immunol Res 8(1):22–31
3. Osborne NJ et al (2011) Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 127(3):668–76, e1–2
4. Leung ASY, Wong GWK, Tang MLK (2018) Food allergy in the developing world. J Allergy Clin Immunol 141(1):76–78, e1
5. Alduraywish SA et al (2016) The march from early life food sensitization to allergic disease: a systematic review and meta-analyses of birth cohort studies. Allergy 71(1):77–89
6. Thomsen SF (2015) Epidemiology and natural history of atopic diseases. Eur Clin Respir J 2(1):1
7. Hill DA, Spergel JM (2018) The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol 120(2):131–137
8. Litonjua AA et al (1998) Parental history and the risk for childhood asthma. Does mother confer more risk than father? Am J Respir Crit Care Med 158(1):176–81
9. Backhed F et al (2015) Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17(5):690–703
10. Heine RG (2018) Food allergy prevention and treatment by targeted nutrition. Ann Nutr Metab 72(Suppl 3):33–45
11. Oddy WH (2017) Breastfeeding, childhood asthma, and allergic disease. Ann Nutr Metab 70(Suppl 2):26–36
12. Wang S et al (2022) Association between breastmilk microbiota and food allergy in infants. Front Cell Infect Microbiol 11
13. Grieger JA et al (2016) In utero programming of allergic susceptibility. Int Arch Allergy Immunol 169(2):80–92
14. Martino D, Prescott S (2011) Epigenetics and prenatal influences on asthma and allergic airways disease. Chest 139(3):640–647
15. Yassour M et al (2016) Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med 8(343):343na81
16. Slob EMA et al (2020) Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study. Eur Respir J 55(4)
17. Pitter G et al (2016) Antibiotic exposure in the first year of life and later treated asthma, a population based birth cohort study of 143,000 children. Eur J Epidemiol 31(1):85–94
18. Biasucci G et al (2010) Mode of delivery affects the bacterial community in the newborn gut. Early Hum Dev 86(Suppl 1):13–15
19. Lin J et al (2021) The associations of caesarean delivery with risk of wheezing diseases and changes of T Cells in children. Front Immunol 12:793762
20. Juhn YJ et al (2005) Mode of delivery at birth and development of asthma: a population-based cohort study. J Allergy Clin Immunol 116(3):510–516
21. Kumar M et al (2020) Microbiome as an immunological modifier. Methods Mol Biol 2055:595–638
22. Guerin LR, Prins JR, Robertson SA (2009) Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update 15(5):517–535
23. Soyer OU et al (2013) Mechanisms of peripheral tolerance to allergens. Allergy 68(2):161–170
24. Daley D (2014) The evolution of the hygiene hypothesis: the role of early-life exposures to viruses and microbes and their relationship to asthma and allergic diseases. Curr Opin Allergy Clin Immunol 14(5):390–396
25. van Mutius E, Vercelli D (2010) Farm living: effects on childhood asthma and allergy. Rev Immunol 10(12):861–868
26. Genuin J et al (2013) The combined effects of family size and farm exposure on childhood hay fever and atopy. Pediatr Allergy Immunol 24(3):293–298
27. Kumar M, Garand M, Al Khodor S (2019) Integrating omics for a better understanding of inflammatory bowel disease: a step towards personalized medicine. J Transl Med 17(1):419
28. Douwes J et al (2008) Farm exposure in utero may protect against asthma, hay fever and eczema. Eur Respir J 32(3):603–611
29. Ege MJ et al (2011) Exposure to environmental microorganisms and childhood asthma. N Engl J Med 364(8):701–709
30. Beckhaus AA et al (2015) Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta-analysis. Allergy 70(12):1588–1604
31. Calzada D et al (2018) Immunological mechanisms in allergic diseases and allergen tolerance: the role of treg cells. J Immunol Res 2018:6012053
32. Fujimura KE et al (2016) Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med 22:1187
33. Penders J et al (2007) Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 56(5):661–667
34. Paller AS et al (2019) The microbiome in patients with atopic dermatitis: a systematic review and meta-analysis of 143,000 children. Eur J Epidemiol 31:85–94
35. Honda K, Littman DR (2016) The microbiota in adaptive immunity and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med 8(343):343ra81
36. Nutten S (2015) Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 66(Suppl 1):8–16
37. Barbarot S et al (2018) Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 73(6):1284–1293
38. Knoer T, Meholidić-Fetahović A, Mehmedagić A (2011) Stratum corneum hydration and skin surface pH in patients with atopic dermatitis. Acta Dermatovenerol Croat 19(4):242–247
39. Vu AT et al (2010) Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 126(5):985–93, 993.e1–3
41. Naik S et al (2015) Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature 520(7545):104–108
42. Ridaura VK et al (2018) Contextual control of skin immunity and inflammation by Corynebacterium. J Exp Med 215(3):785–799
43. Kong HH et al (2012) Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 22(5):850–859
44. Baker BS (2006) The role of microorganisms in atopic dermatitis. Clin Exp Immunol 144(1):1–9
45. Chng KR et al (2016) Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat Microbiol 1(9):16106
46. Byrd AL et al (2017) Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl Med 9(397)
47. Simpson EL et al (2018) Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Invest Dermatol 138(10):2224–2233
48. Watanabe S et al (2003) Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol 111(3):587–591
49. Kalliomäki M et al (2001) Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 107(1):129–134
50. Lyons A et al (2010) Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. Clin Exp Allergy 40(5):811–819
51. Gehring U et al (2001) Exposure to endotoxin decreases the risk of atopic eczema in infancy: a cohort study. J Allergy Clin Immunol 108(5):847–854
52. Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453(7195):620–625
53. Round JL, Mazmanian SK (2010) Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107(27):12204–12209
54. Abrahamsson TR et al (2012) Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol 129(2):434–440, e41–2
55. Nibbering B, Ubags NDJ (2020) Microbial interactions in the atopic march. Clin Exp Immunol 199(1):12–23
56. Doreswamy V, Peden DB (2011) Modulation of asthma by endotoxin. Clin Exp Allergy 41(1):9–19
57. Koh A et al (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165(6):1332–1345
58. De Benedetto A et al (2011) Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 127(3):773–86, e1–7
59. Song H et al (2016) Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol 137(3):852–860
60. Reddel S et al (2019) Gut microbiota profile in children affected by atopic dermatitis. Mol Microbiol 108(5):847–854
61. Furusawa Y et al (2013) Commensal microbe-derived butyrate mediates factor prevents intestinal inflammatory disease. Nature 453(7195):620–625
62. Loh W, Tang ML (2018) The epidemiology of food allergy in the United States. J Allergy Clin Immunol 137(3):852–860
63. Sicherer SH, Sampson HA (2014) Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 133(2):291-307.e5
64. Sicherer SH, Sampson HA (2006) Food allergy. J Allergy Clin Immunol 117(2 Supplement 2):S470–S475
65. Yu W, Freeland DMH, Nadeau KC (2016) Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol 16(12):751–765
66. Tordesillas L, Berin MC (2018) Mechanisms of oral tolerance. Clin Rev Allergy Immunol 55(2):107–117
67. Tan J et al (2016) Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep 15(12):2809–2824
68. Satissukasana P et al (2018) Regulatory immune mechanisms in tolerance to food allergy. Front Immunol 9:2939
69. Akdis CA, Akdis M (2014) Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest 124(11):4678–4680
70. Di Costanzo M et al (2020) Gut microbiome modulation for preventing and treating pediatric food allergies. Int J Mol Sci 21(15):5275
71. Paparo L et al (2021) Butyrate as a bioactive human milk protective component against food allergy. Allergy 76(5):1398–1415
72. Zhao W, Ho HE, Bunyavanich S (2019) The gut microbiome in food allergy. Ann Allergy Asthma Immunol 122(3):276–282
73. Klampfer L et al (2003) Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res 1(11):855–862
74. Lee WJ, Hase K (2014) Gut microbiota-generated metabolites in animal health and disease. Nat Chem Biol 10(6):416–424
75. Sokol H et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105(43):16731–16736
76. Han KJ et al (2015) Anticancer and anti-inflammatory activity of probiotic Lactococcus lactis NK34. J Microbiol Biotechnol 25(10):1697–1701
77. Azad MB et al (2015) Infant gut microbiota and food sensitization: associations in the first year of life. Clin Exp Allergy 45(3):632–643
78. Savage JH et al (2018) A prospective microbiome-wide association study of food sensitization and food allergy in early childhood. Allergy 73(1):145–152
79. Yatsunenko T et al (2012) Human gut microbiome viewed across ages. Nature 486(7402):222–227
80. McCoy KD, Thomson CA (2018) The impact of maternal microbial and microbial colonization in early life on hematopoiesis. J Immunol 108(5):2519–2526
81. Kubinak JL et al (2015) MyD88 signaling in T cells directs IgA-mediated tolerance to food allergy. Allergy 76(5):1398–1415
89. Meyer EH et al (2006) Glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proc Natl Acad Sci U S A 103(8):2782–2787
90. Larsen JM et al (2015) Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp., promote Toll-like receptor 2-independent lung inflammation and pathology. Immunology 144(2):333–42
91. Naleway AL (2004) Asthma and atopy in rural children: is farming protective? Clin Med Res 2(1):5–12
92. von Mutius E, Vercelli D (2010) Farm living: effects on childhood asthma and allergy. Nat Rev Immunol 10:361
93. Wlasiuk G, Vercelli D (2012) The farm effect, or: when, what and how a farming environment protects from asthma and allergic disease. Curr Opin Allergy Clin Immunol 12(5):461–466
94. Schuijs MJ et al (2015) Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science 349(6252):1106–1110
95. Kakli HA, Riley TD (2016) Allergic rhinitis. Prim Care 43(3):465–475
96. Wheatley LM, Togias A (2015) Clinical practice. Allergic rhinitis. N Engl J Med 372(5):456–463
97. Chiu CY et al (2017) Airway microbial diversity is inversely associated with mite-sensitized rhinitis and asthma in early childhood. Sci Rep 7(1):1820
98. Yu W et al (2015) Reduced airway microbiota diversity is associated with elevated allergic respiratory inflammation. Ann Allergy Asthma Immunol 115(1):63–68
99. Marri PR et al (2013) Asthma-associated differences in microbial composition of induced sputum. J Allergy Clin Immunol 131(2):346–352.e3
100. Huang YJ, Boushey HA (2015) The microbiome in asthma. J Allergy Clin Immunol 135(1):25–30
101. Sverrild A et al (2017) Eosinophilic airway inflammation and pathogenesis independent of conventional CD4+ T cells. Proc Natl Acad Sci U S A 103(8):2782–2787
102. Green BJ et al (2014) Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. Plos One 9(6):e100645
103. Taylor SL et al (2018) Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Immunol 140(2):407–417.e11
104. Goleva E et al (2013) Reduced airway microbiota diversity is associated with elevated allergic respiratory inflammation. Am J Respir Crit Care Med 188(10):1193–1201
105. Abrahamsson TR et al (2014) Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy 44(6):842–850
106. Stiensma LT et al (2016) Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma. Clin Sci 130(23):2199–2207
107. Durack J et al (2018) Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation. Nat Commun 9(1):707
108. Jimenez E et al (2005) Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol 51(4):270–274
109. Stout MJ et al (2013) Identification of intracellular bacteria in the basal plate of the human placenta in term and preterm gestations. Am J Obstet Gynecol 208(3):226, e1–7
110. Aagaard K et al (2014) The placenta harbors a unique microbiome. Sci Transl Med 6(237):237ra65
111. Al Alam D et al (2020) Human fetal lungs harbor a microbiome signature. Am J Respir Crit Care Med 201(8):1002–1006
112. Rackaityte E et al (2020) Viable bacterial colonization is highly limited in the human intestine in utero. Nat Med 26(4):599–607
113. Senn V et al (2020) Microbial colonization from the fetus to early childhood - a comprehensive review. Front Cell Infect Microbiol 10:573735
114. Stinson LF et al (2019) The Not-so-sterile womb: evidence that the human fetus is exposed to bacteria prior to birth. Front Microbiol 10:1124
115. Blaser MJ et al (2021) Lessons learned from the prenatal microbiome controversy. Microbiome 9(1):8
116. Walter J, Hornef MW (2021) A philosophical perspective on the prenatal in utero microbiome debate. Microbiome 9(1):5
117. Mishra A et al (2021) Microbial exposure during early human development primes fetal immune cells. Cell 184(13):3394–3409, e20
118. Prince AL et al (2015) The perinatal microbiome and pregnancy: moving beyond the vaginal microbiome. Cold Spring Harb Perspect Med 5(6)
119. Wampach L et al (2018) Birth mode is associated with earliest strain-conferring gut microbiome functions and immunostimulatory potential. Nat Commun 9(1):5091
120. Ferretti P et al (2018) Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe 24(1):133–145, e5
121. Sordillo JE et al (2010) Multiple microbial exposures in the home may protect against asthma or allergy in childhood. Clin Exp Allergy 40(6):902–910
122. Gensollen T et al (2016) How colonization by microbiota in early life shapes the immune system. Science 352(6285):539–544
123. Keag OE, Norman JE, Stock SJ (2018) Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: systematic review and meta-analysis. PLoS Med 15(1):e1002494
124. Shao Y et al (2019) Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 574(7776):117–121
125. Dominguez-Bello MG et al (2016) Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med 22(3):250–253
126. Bezirtzoglou E, Tsiotisias A, Welling GW (2011) Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe 17:478–482
127. Tilburgs T, Scherjon SA, Claas FH (2010) Major histocompatibility complex (MHC)-mediated immune regulation of decidual leukocytes at the fetal-maternal interface. J Reprod Immunol 85(1):58–62
128. Schreurs R et al (2019) Human fetal TNF-α-cytokine-producing CD4+ effector memory T cells promote intestinal development and mediate inflammation early in life. Immunity 50(2):462-476.e8
129. Blom B, Res PC, Spits H (1998) T cell precursors in man and mouse. Crit Rev Immunol 18(4):371–388
130. Haynes BF, Heinly CS (1995) Early human T cell development: analysis of the human thymus at the time of initial entry of hematopoietic stem cells into the fetal thymic microenvironment. J Exp Med 181(4):1445–1458
131. Park JE et al (2020) Prenatal development of human immunity. Science 368(6491):600–603
132. Vuillermont PJ et al (2017) The maternal microbiome during pregnancy and allergic disease in the offspring. Semin Immunopathol 39(6):669–675
133. Stokholm J et al (2017) Preeclampsia associates with asthma, allergy, and eczema in childhood. Am J Respir Crit Care Med 195(5):614–621
134. Michaelsson J et al (2006) Regulation of T cell responses in the developing human fetus. J Immunol 176(10):5741–5748
135. Mold JE et al (2008) Maternal albuminigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 322(5907):1562–1565
136. La Rocca C et al (2014) The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett 162(1 Pt A):41–8

137. Kumar M et al (2021) Vaginal microbiota and cytokine levels predict preterm delivery in Asian women. Front Cell Infect Microbiol 11:639665

138. McGovern N et al (2017) Human fetal dendritic cells promote prenatal T-cell immune suppression through arginase-2. Nature 546(7660):662–666

139. Basha S, Surendran N, Pichichero M (2014) Immune responses in neonates. Expert Rev Clin Immunol 10(9):1171–1184

140. Cosmi L et al (2008) Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 205(8):1903–1916

141. Debock I, Flamand V (2014) Unbalanced neonatal cD4(+) T-cell immunity. Front Immunol 5:393

142. Peterson J et al (2009) The NIH human microbiome project. Genome Res 19(12):2317–2323

143. Lee N, Kim WU (2017) Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med 49(5):e340

144. Yang BH et al (2016) Foxp3(+) T cells expressing RORgammaT represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol 9(2):444–457

145. Lathrop SK et al (2011) Peripheral education of the immune system by colonic commensal microbiota. Nature 478(7368):250–254

146. Kim KS et al (2016) Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science 351(6275):858–863

147. Bacher P et al (2016) Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell 167(4):1067-1078.e16

148. Bilate AM, Lafaille JJ (2012) Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 30:733–758

149. Kim SV et al (2013) GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science 340(6139):1456–1459

150. Bacher P, Scheffold A (2018) Antigen-specific regulatory T-cell responses against aeroantigens and their role in allergy. Mucosal Immunol

151. Shamji MH, Durham SR (2017) Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Clin Immunol 140(6):1485–1498

152. Wambere E et al (2017) A phenotypically and functionally distinct human TH2 cell subgroup is associated with allergic disorders. Sci Transl Med 9(401)

153. Bangert C et al (2021) Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Ralpha blockade. Sci Immunol 6(55)

154. Zhu J, Yamane H, Paul WE (2010) Differentiation of effectr CD4 T cell populations (*). Annu Rev Immunol 28:445–489

155. Roychoudhuri R et al (2013) BACH2 represses effector program to stabilize T(reg)-mediated immune homeostasis. Nature 498(7455):506–510

156. Herbst T et al (2011) Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am J Respir Crit Care Med 184(2):198–205

157. McCoy KD et al (2006) Natural IgE production in the absence of MHC Class II cognate help. Immunity 24(3):329–339

158. Josefowicz SZ et al (2012) Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482(7385):395–399

159. Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. Cell 157(1):121–141

160. Ohnmacht C et al (2015) Mucosal immunology. The microbiota regulates type 2 immunity through RORgammaT(+) T cells. Science 349(6251):989–93

161. Russell SL et al (2012) Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 13(5):440–447

162. Bhaskaran N et al (2018) Role of short chain fatty acids in controlling tregs and immunopathology during mucosal infection. Front Microbiol 9:1995

163. Smith PM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic T reg cell homeostasis. Science 341(6145):569–573

164. Thio CL et al (2018) Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate. J Allergy Clin Immunol 142(6):1867–1883, e12

165. Pandiyang P et al (2019) Microbiome dependent regulation of tregs and Th17 Cells in mucosa. Front Immunol 10:426

166. Ridlon JM et al (2016) Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7(1):22–39

167. Campbell C et al (2020) Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581(7809):475–479

168. Fujimura KE et al (2016) Neonatal gut microbiota associates with childhood multi sensitized atopy and T cell differentiation. Nat Med 22(10):1187–1191

169. Levan SR et al (2019) Elevated faecal 12,13-diHOME concentration in neonates at high risk for asthma is produced by gut bacteria and impedes immune tolerance. Nat Microbiol 4(11):1851–1861

170. Round JL et al (2011) The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332(6032):974–977

171. Verma R et al (2018) Cell surface polysaccharides of bifidobacterium bifidum induce the generation of Foxp3(+) regulatory T cells. Sci Immunol 3(28)

172. Kunisawa J et al (2012) A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo. PLoS One 7(2):e32094

173. Singh N et al (2014) Activation of Gpr109a, receptor for nia cin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40(1):128–139

174. Wang Y et al (2021) Interaction of maternal asthma history and plasma folate levels on child asthma risk in the Boston Birth Cohort. Pediatr Pulmonol 56(12):372S–3736

175. McGowan EC et al (2020) Association between folate metabolism and the development of food allergy in children. J Allergy Clin Immunol Pract 8(1):132–140, e5

176. Karimi K et al (2009) Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 179(3):186–193

177. Cervantes-Barragan L et al (2017) Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8alphaalpha(+) T cells. Science 357(6353):806–810

178. Henrick BM et al (2021) Bifidobacteria-mediated immune system imprinting early in life. Cell 184(15):3884–3898, e11

179. Strachan DP (1989) Hay fever, hygiene, and household size. BMJ 299(6710):1259–1260

180. Shirakawa T et al (1997) The inverse association between tuber cin responses and atopic disorder. Science 275(5296):77–79

181. Illi S et al (2001) Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 322(7283):390–395

182. Figueiredo CA et al (2013) Environmental conditions, immunologic phenotypes, atopy, and asthma: new evidence of how the hygiene hypothesis operates in Latin America. J Allergy Clin Immunol 131(4):1064–1068, e1
183. Silverberg JI et al (2010) Association between varicella zoster virus infection and atopic dermatitis in early and late childhood: a case-control study. J Allergy Clin Immunol 126(2):300–305
184. Bremner SA et al (2008) Infections presenting for clinical care in early life and later risk of hay fever in two UK birth cohorts. Allergy 63(3):274–283
185. Benn CS et al (2004) Cohort study of sibling effect, infectious diseases, and risk of atopic dermatitis during first 18 months of life. BMJ 328(7450):1223
186. Dunder T et al (2007) Infections in child day care centers and later development of asthma, allergic rhinitis, and atopic dermatitis: prospective follow-up survey 12 years after controlled randomized hygiene intervention. Arch Pediatr Adolesc Med 161(10):972–977
187. Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347(12):911–920
188. Steinman L (2007) A brief history of T(H)17, the first major subset of T helper cells. Trends Immunol 28(3):112–118
189. Simpson CR et al (2002) Coincidence of immune-mediated diseases and rheumatoid arthritis. Semin Arthritis Rheum 31(4):293–302
190. Smew AI et al (2020) Familial coaggregation of asthma and type 1 diabetes in children. JAMA Netw Open 3(3):e200834
191. Guo R et al (2017) Atopy in children with juvenile systemic lupus erythematosus is associated with severe disease. PLoS One 12(5):e017774
192. Krishna MT et al (2019) Allergic diseases and long-term risk of autoimmunity disorders: longitudinal cohort study and cluster analysis. Eur Respir J 54(5)
193. Kreiner E et al (2017) Shared genetic variants suggest common pathways in allergy and autoimmune diseases. J Allergy Clin Immunol 140(3):771–781
194. Schabussova I, Wiedermann U (2007) Probiotics in primary prevention of atopic dermatitis. Allergy 63(3):274–283
195. Elliott AM et al (2005) Helminth infection during pregnancy and development of infantile eczema. JAMA 294(16):2032–2034
196. Cooper PJ et al (2018) Effect of early-life geholmium infections on the development of wheezing at 5 years of age. Am J Respir Crit Care Med 197(3):364–372
197. Endara P et al (2010) Long-term periodic anthelmintic treatments are associated with increased allergen skin reactivity. Clin Exp Allergy 40(11):1669–1677
198. Leonardi-Bee J, Pritchard D, Britton J (2006) Asthma and current intestinal parasite infection: systematic review and meta-analysis. Am J Respir Crit Care Med 174(5):514–523
199. Alexandre-Silva GM et al (2018) The hygiene hypothesis at a glance: early exposures, immune mechanism and novel therapies. Acta Trop 188:16–26
200. Araujo MI et al (2000) Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. Int Arch Allergy Immunol 123(2):145–148
201. van Tilburg Bernardes E, Arrieta MC (2017) Hygiene hypothesis in asthma development: is hygiene to blame? Arch Med Res 48(8):717–726
202. Bloomfield SF et al (2016) Time to abandon the hygiene hypothesis: new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. Perspect Public Health 136(4):213–224
203. Rook GA, Martinelli R, Brunet LR (2003) Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr Opin Allergy Clin Immunol 3(5):337–342
204. Haahleta T et al (2013) The biodiversity hypothesis and allergic disease: world allergy organization position statement. World Allergy Organ J 6(1):3
205. Lambrechts BN, Hammad H (2017) The immunology of the allergy epidemic and the hygiene hypothesis. Nat Immunol 18(10):1076–1083
206. Parfrey LW et al (2014) Communities of microbial eukaryotes in the mammalian gut within the context of environmental eukaryotic diversity. Front Microbiol 5:298
207. Venkatakrishnan A et al (2021) Evolution of bacteria in the human gut in response to changing environments: an invisible player in the game of health. Comput Struct Biotechnol J 19:752–758
208. Sonnenburg ED et al (2016) Diet-induced extinctions in the gut microbiota compound over generations. Nature 529(7585):212–215
209. Byndloss MX et al (2017) Microbiota-activated PPAR-gamma signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357(6351):570–575
210. Foegeding NJ, Jones ZS, Byndloss MX (2021) Western lifestyle as a driver of dysbiosis in colorectal cancer. Dis Model Mech 14(5)
211. Smits SA et al (2017) Seasonal cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania. Science 357(6353):802–806
212. Tyakht AV et al (2013) Human gut microbiota community structures in urban and rural populations in Russia. Nat Commun 4:2469
213. Fan Y, Pedersen O (2021) Gut microbiota in human metabolic health and disease. Rev Microbiol 19(1):55–71
214. Komlosi ZI et al (2021) Cellular and molecular mechanisms of allergic asthma. Mol Aspects Med 100995
215. Kelly CR et al (2014) Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109(7):1065–1071
216. NCT02960074 (2016) https://clinicaltrials.gov/ct2/show/NCT02960074. Accessed 24 April 2022
217. Feehley T et al (2019) Healthy infants harbor intestinal bacteria that protect against food allergy. Nat Med 25(3):448–453
218. Myles IA et al (2018) First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight 3(9)
219. Nakatsuji T et al (2021) Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nat Med 27(4):700–709
220. Tang ML et al (2015) Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol 135(3):737–44 e8
221. Hol J et al (2008) The acquisition of tolerance toward cow’s milk through probiotic supplementation: a randomized, controlled trial. J Allergy Clin Immunol 121(6):1448–1454
222. Berni Canani R et al (2012) Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: a randomized trial. J Allergy Clin Immunol 129(2):580–2, 582 e1–5
223. Candy DCA et al (2018) A symbiotic-containing amino-acid-based formula improves gut microbiota in non-IgE-mediated allergic infants. Pediatr Res 83(3):677–686
224. Wickens K et al (2012) A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy 42(7):1071–1079
225. Boyle RJ et al (2011) Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. J Allergy Clin Immunol 128(1):197–203 e1–2
226. Kalliomaki M et al (2001) Probiotics in primary prevention of allergic asthma: world allergy organization position statement. World Allergy Organ J 6(1):3
227. Dotterud CK et al (2010) Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol 163(3):616–623
228. Peldan P et al (2017) Perinatal probiotics decreased eczema up to 10 years of age, but at 5–10 years, allergic rhino-conjunctivitis was increased. Clin Exp Allergy 47(7):975–979
229. Azad MB et al (2013) Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: systematic review and meta-analysis. BMJ 347:f6471
230. Zuccotti G et al (2015) Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy 70(11):1356–1371
231. Wei X et al (2020) Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials. J Asthma 57(2):167–178
232. Fiocchi A et al (2015) World allergy organization-mcmaster university guidelines for allergic disease prevention (GLAD-P): probiotics. World Allergy Organ J 8(1):4
233. Maizels RM (2020) Regulation of immunity and allergy by helminth parasites. Allergy 75(3):524–534
234. Rodrigues LC et al (2008) Early infection with Trichuris trichiura and allergen skin test reactivity in later childhood. Clin Exp Allergy 38(11):1769–1777
235. Scientific America (2010) https://www.scientificamerican.com/article/helminthic-therapy-mucus/. Accessed 24 April 2022
236. Feary JR et al (2010) Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy 40(2):299–306
237. Feary J et al (2009) Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clin Exp Allergy 39(7):1060–1068
238. Bager P et al (2010) Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 125(1):123–30 e1–3
239. Jouvin MH, Kinet JP (2012) Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J Allergy Clin Immunol 130(1):3–10; quiz 11–2
240. Summers RW et al (2005) Trichuris suis therapy in Crohn’s disease. Gut 54(1):87–90
241. Kumar M et al (2021) Omouma: a prospective mother and child cohort aiming to identify early biomarkers of pregnancy complications in women living in Qatar. BMC Pregnancy Childbirth 21(1):570
242. Kao D et al (2017) Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. JAMA 318(20):1985–1993
243. Campbell C et al (2018) Extrathymically generated regulatory T Cells establish a niche for intestinal border-dwelling bacteria and affect physiologic metabolite balance. Immunity 48(6):1245–1257, e9

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.